1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

ABSTRACT

Compounds of Formula (I), their preparation and use in preventing or treating bacterial infection is disclosed.

RELATED PATENT APPLICATIONS

This application claims the benefit of Indian Provisional PatentApplication No. 2412/MUM/2011 filed on Aug. 27, 2011, the disclosures ofwhich are incorporated herein by reference in its entirety as if fullyrewritten herein. All references including patents, patent applications,and literature cited in the specification are expressly incorporatedherein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to nitrogen containing compounds, theirpreparation and their use in preventing and/or treating bacterialinfections.

BACKGROUND OF THE INVENTION

Emergence of bacterial resistance to known antibacterial agents isbecoming a major challenge in treating bacterial infections. One wayforward to treat bacterial infections, and especially those caused byresistant bacteria, is to develop newer antibacterial agents that canovercome the bacterial resistance. Coates et al. (Br. J. Pharmacol.2007; 152(8), 1147-1154.) have reviewed novel approaches to developingnew antibiotics. However, the development of new antibacterial agents isa challenging task. For example, Gwynn et al. (Annals of the New YorkAcademy of Sciences, 2010, 1213: 5-19) have reviewed the challenges inthe discovery of antibacterial agents.

Several antibacterial agents have been described in the prior art (forexample, see PCT International Application Nos. PCT/US2010/060923,PCT/EP2010/067647, PCT/US2010/052109, PCT/US2010/048109,PCT/GB2009/050609, PCT/EP2009/056178 and PCT/US2009/041200). However,there remains a need for potent antibacterial agents for preventingand/or treating bacterial infections, including those caused by bacteriathat are resistant to known antibacterial agents.

The inventors have surprisingly discovered nitrogen containing compoundswith antibacterial properties.

SUMMARY OF THE INVENTION

Accordingly there are provided nitrogen containing compounds, methodsfor preparation of these compounds, pharmaceutical compositionscomprising these compounds, and method for preventing or treatingbacterial infection in a subject using these compounds.

In one general aspect, there are provided compounds of Formula (I):

or a stereoisomer or a pharmaceutically acceptable salt thereof;wherein:

-   -   R₁ is:        -   (a) hydrogen,        -   (b) (CO)_(n)—R₃,        -   (c) COOR₄, or        -   (d) COCH₂COR₃    -   n is 0, 1 or 2;    -   R₂ is:        -   (a) SO₃M,        -   (b) SO₂NH₂,        -   (c) PO₃M,        -   (d) CH₂COOM,        -   (e) CF₂COOM,        -   (f) CHFCOOM, or        -   (g) CF₃;    -   M is hydrogen or a cation;    -   R₃ is:        -   (a) hydrogen,        -   (b) C₁-C₆ alkyl optionally substituted with one or more            substituents independently selected from halogen, OR₅, CN,            COOR₅, CONR₆R₇, NR₆R₇, NR₅COR₈, NR₅CONR₆R₇, heterocyclyl,            heteroaryl, cycloalkyl or aryl,        -   (c) CN,        -   (d) NR₆R₇,        -   (e) CONR₆R₇,        -   (f) NHCONR₆R₇,        -   (g) aryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇,        -   (h) heterocyclyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, NHC(NH)NR₆R₇, or NHCONR₆R₇,        -   (i) heteroaryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇,        -   (j) cycloalkyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇,        -   (k) cycloalkyl substituted with C₁-C₆ alkyl wherein C₁-C₆            alkyl is further substituted with one or more substituents            independently selected from OR₅, NR₆R₇, halogen, CN, or            CONR₆R₇, or        -   (l) OR₈;    -   R₄ is:        -   (a) hydrogen,        -   (b) C₁-C₆ alkyl optionally substituted with one or more            substituents independently selected from halogen, OR₅, CN,            COOR₅, CONR₆R₇, NR₆R₇, NR₅COR₈, heterocyclyl, heteroaryl,            cycloalkyl or aryl,        -   (c) aryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇,        -   (d) heterocyclyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇,        -   (e) heteroaryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇, or        -   (f) cycloalkyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇;    -   R₅ and R₈ are each independently:        -   (a) hydrogen, or        -   (b) C₁-C₆ alkyl optionally substituted with one or more            substituents independently selected from halogen, CN,            CONR₆R₇, NR₆R₇, heterocyclyl, heteroaryl, cycloalkyl or            aryl;    -   R₆ and R₇ are each independently:        -   (a) hydrogen,        -   (b) C₁-C₆ alkyl optionally substituted with one or more            substituents independently selected from halogen, OR₅, CN,            COOR₅, CONR₅R₈, NR₅R₈, NR₅COR₈, heterocyclyl, heteroaryl,            cycloalkyl or aryl,        -   (c) aryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈,        -   (d) heterocyclyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈,        -   (e) heteroaryl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈,        -   (f) cycloalkyl optionally substituted with one or more            substituents independently selected from C₁-C₆ alkyl, OR₅,            NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,            OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈, or        -   (g) R₆ and R₇ are joined together to form a four to seven            member ring.

In another general aspect, there are provided pharmaceuticalcompositions comprising a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of acompound of Formula (I) or a stereoisomer or a pharmaceuticallyacceptable salt thereof.

In another general aspect, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a compound of Formula (I) or a stereoisomer or apharmaceutically acceptable salt thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising a compound of Formula (I) or astereoisomer or a pharmaceutically acceptable salt thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising a compoundof Formula (I) or a stereoisomer or a pharmaceutically acceptable saltthereof.

In another general aspect, there are provided pharmaceuticalcompositions comprising: (a) a compound of Formula (I), or astereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof.

In another general aspect, there are provided pharmaceuticalcompositions comprising: (a) a compound of Formula (I), or astereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In another general aspect, there are provided pharmaceuticalcompositions comprising: (a) a compound of Formula (I), or astereoisomer or a pharmaceutically acceptable salt thereof, (b) at leastone beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof,and (c) at least one antibacterial agent or a pharmaceuticallyacceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one antibacterial agent or apharmaceutically acceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, (b) atleast one beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof,and (c) at least one antibacterial agent or a pharmaceuticallyacceptable derivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof, and (c) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, and (b) at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one antibacterial agent or apharmaceutically acceptable derivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, and (b) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In another general aspect, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof, and (c) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In yet another general aspect, there is provided a method for preventingor treating a bacterial infection in a subject, said infection beingcaused by bacteria producing one or more beta-lactamase enzymes, whereinthe method comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, (b) at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof, and (c) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In another general aspect, there are provided methods for increasingantibacterial effectiveness of a antibacterial agent in a subject, saidmethod comprising co-administering said antibacterial agent or apharmaceutically acceptable derivative thereof with a pharmaceuticallyeffective amount of a compound of Formula (I) or a stereoisomer or apharmaceutically acceptable salt thereof.

The details of one or more embodiments of the invention are set forth inthe description below. Other features, objects and advantages of theinvention will be apparent from the following description includingclaims.

DETAILED DESCRIPTION OF THE INVENTION

Reference will now be made to the exemplary embodiments, and specificlanguage will be used herein to describe the same. It shouldnevertheless be understood that no limitation of the scope of theinvention is thereby intended. Alterations and further modifications ofthe inventive features illustrated herein, and additional applicationsof the principles of the invention as illustrated herein, which wouldoccur to one skilled in the relevant art and having possession of thisdisclosure, are to be considered within the scope of the invention. Itmust be noted that, as used in this specification and the appendedclaims, the singular forms “a,” “an,” and “the” include plural referentsunless the content clearly dictates otherwise. All references includingpatents, patent applications, and literature cited in the specificationare expressly incorporated herein by reference in their entirety.

The inventors have surprisingly discovered novel nitrogen containingcompounds having antibacterial properties.

The term “C₁-C₆ alkyl” as used herein refers to branched or unbranchedacyclic hydrocarbon radical with 1 to 6 carbon atoms. Typical,non-limiting examples of “C₁-C₆ alkyl” include methyl, ethyl, n-propyl,iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl,n-hexyl and the like. The “C₁-C₆ alkyl” may be unsubstituted, orsubstituted with one or more substituents. Typical, non-limitingexamples of such substituents include halogen, alkoxy, CN, COOH, CONH₂,OH, —NH₂, —NHCOCH₃, cycloalkyl, heterocyclyl, heteroaryl, aryl and thelike.

The term “cycloalkyl” as used herein refers to three to seven membercyclic hydrocarbon radicals. The cycloalkyl group optionallyincorporates one or more double or triple bonds, or a combination ofdouble bonds and triple bonds, but which is not aromatic. Typical,non-limiting examples of cycloalkyl groups include cyclopropane,cyclobutane, cyclopentane, cyclohexane, and cycloheptane. The cycloalkylmay be unsubstituted, or substituted with one or more substituents.Typical, non-limiting examples of such substituents include C₁-C₆ alkyl,halogen, alkoxy, CN, COOH, CONH₂, OH, NH₂, NHCOCH₃, heterocyclyl,heteroaryl, aryl, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, —OSO₂-aryl and thelike.

The term “heterocyclyl” as used herein refers to four to seven membercycloalkyl group containing one or more heteroatoms selected fromnitrogen, oxygen or sulfur. The heterocycloalkyl group optionallyincorporates one or more double or triple bonds, or a combination ofdouble bonds and triple bonds, but which is not aromatic. Typical,non-limiting examples of heterocycloalkyl groups include azetidine,pyrrolidine, 2-oxo-pyrrolidine, imidazolidin-2-one, piperidine, oxazine,thiazine, piperazine, piperazin-2,3-dione, morpholine, thiamorpholine,azapane, and the like. The heterocycloalkyl may be unsubstituted, orsubstituted with one or more substituents. Typical, non-limitingexamples of such substituents include C₁-C₆ alkyl, halogen, alkoxy, CN,COOH, CONH₂, OH, NH₂, NHCOCH₃, heterocyclyl, heteroaryl, aryl,SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl and the like.

The term “aryl” as used herein refers to a monocyclic or polycyclicaromatic hydrocarbon. Typical, non-limiting examples of aryl groupsinclude phenyl, naphthyl, anthracenyl, fluorenyl, phenanthrenyl, and thelike. The aryl group may be unsubstituted, or substituted with one ormore substituents. Typical, non-limiting examples of such substituentsinclude C₁-C₆ alkyl, halogen, alkoxy, CN, COOH, CONH₂, OH, NH₂, NHCOCH₃,heterocyclyl, heteroaryl, aryl, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,OSO₂-aryl and the like.

The term “heteroaryl” as used herein refers to a monocyclic orpolycyclic aromatic hydrocarbon group wherein one or more carbon atomshave been replaced with heteroatoms selected from nitrogen, oxygen, andsulfur. If the heteroaryl group contains more than one heteroatom, theheteroatoms may be the same or different. Typical, non-limiting exampleof heteroaryl groups include 1,2,4-oxadiazol, 1,3,4-oxadiazol,1,3,4-thiadiazol, 1,2,3,4-tetrazol, 1,3-oxazol, 1,3-thiazole, pyridine,pyrimidine, pyrazine, pyridazine, furan, pyrrol, thiophene, imidazole,pyrazole, benzofuran, benzothiophene, benzimidazole, benzoxazole,benzothiazole, thiazole, and the like. The heteroaryl group may beunsubstituted, or substituted with one or more substituents. Typical,non-limiting examples of such substituents include C₁-C₆ alkyl, halogen,alkoxy, CN, COOH, CONH₂, OH, NH₂, NHCOCH₃, heterocyclyl, heteroaryl,aryl, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl and the like.

The term “stereoisomers” as used herein refers to compounds that haveidentical chemical constitution, but differ with regard to thearrangement of their atoms or groups in space. The compounds of Formula(I) may contain asymmetric or chiral centers and, therefore, exist indifferent stereoisomeric forms. It is intended, unless specifiedotherwise, that all stereoisomeric forms of the compounds of Formula (I)as well as mixtures thereof, including racemic mixtures, form part ofthe present invention. In addition, all geometric and positional isomers(including cis and trans-forms) as well as mixtures thereof, are alsoembraced within the scope of the invention. In general, a reference to acompound is intended to cover its stereoisomers and mixture of variousstereoisomers.

The term “optionally substituted” as used herein means that substitutionis optional and therefore includes both unsubstituted and substitutedatoms and moieties. A “substituted” atom or moiety indicates that anyhydrogen on the designated atom or moiety can be replaced with aselection from the indicated substituent group, provided that the normalvalency of the designated atom or moiety is not exceeded, and that thesubstitution results in a stable compound.

The term “pharmaceutically acceptable salt” as used herein refers to oneor more salts of a given compound which possesses the desiredpharmacological activity of the free compound and which are neitherbiologically nor otherwise undesirable. In general, the“pharmaceutically acceptable salts” refer to salts that are suitable foruse in contact with the tissues of human and animals without unduetoxicity, irritation, allergic response and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M. Berge, etal. (J. Pharmaceutical Sciences, 66: 1-19 (1977)), incorporated hereinby reference in its entirety, describes various pharmaceuticallyacceptable salts in details.

In general, the compounds according to the invention contain basic (e.g.nitrogen atoms) as well as acid moieties (e.g. compounds of Formula (I)wherein M is hydrogen). A person of skills in the art would appreciatethat such compounds, therefore, can form acidic salts (formed withinorganic and/or organic acids), as well as basic salts (formed withinorganic and/or organic bases). Such salts can be prepared usingprocedures described in the art. For example, the basic moiety can beconverted to its salt by treating a compound with a suitable amount ofacid. Typical, non-limiting examples of such suitable acids includehydrochloric acid, trifluoroacetic acid, methanesulphonic acid, or thelike. Alternatively, the acid moiety may be converted into its salt bytreating with a suitable base. Typical non-limiting examples of suchbases include sodium carbonate, sodium bicarbonate, potassium carbonate,potassium bicarbonate or the like. In case of compounds containing morethan one functional groups capable of being converted into salt, eachsuch functional group may be converted to salt independently. Forexample, in case of compounds containing two basic nitrogen atoms, onebasic nitrogen can form salt with one acid while the other basicnitrogen can form salt with another acid. Some compounds according tothe invention contain both, acidic as well as basic moieties, and thuscan form inner salts or corresponding zwitterions. In general, allpharmaceutically acceptable salt forms of compounds of Formula (I)according to invention including acid addition salts, base additionsalts, zwitterions or the like are contemplated to be within the scopeof the present invention and are generically referred to aspharmaceutically acceptable salts.

The term “halogen” or “halo” as used herein refers to chlorine, bromine,fluorine, or iodine.

The term “infection” or “bacterial infection” as used herein includespresence of bacteria, in or on a subject, which, if its growth wereinhibited, would result in a benefit to the subject. As such, the term“infection” in addition to referring to the presence of bacteria alsorefers to normal flora, which is not desirable. The term “infection”includes infection caused by bacteria.

The term “treat”, “treating” or “treatment” as used herein refers toadministering a medicament, including a pharmaceutical composition, orone or more pharmaceutically active ingredients, for prophylactic and/ortherapeutic purposes. The term “prophylactic treatment” refers totreating a subject who is not yet infected, but who is susceptible to,or otherwise at a risk of infection (preventing the bacterialinfection). The term “therapeutic treatment” refers to administeringtreatment to a subject already suffering from infection. The terms“treat”, “treating” or “treatment” as used herein also refer toadministering compositions or one or more of pharmaceutically activeingredients discussed herein, with or without additionalpharmaceutically active or inert ingredients, in order to: (i) reduce oreliminate either a bacterial infection or one or more symptoms of thebacterial infection, or (ii) retard the progression of a bacterialinfection or of one or more symptoms of the bacterial infection, or(iii) reduce the severity of a bacterial infection or of one or moresymptoms of the bacterial infection, or (iv) suppress the clinicalmanifestation of a bacterial infection, or (v) suppress themanifestation of adverse symptoms of the bacterial infection.

The term “pharmaceutically effective amount” or “therapeuticallyeffective amount” or “effective amount” as used herein refers to anamount, which has a therapeutic effect or is the amount required toproduce a therapeutic effect in a subject. For example, atherapeutically or pharmaceutically effective amount of an antibacterialagent or a pharmaceutical composition is the amount of the antibacterialagent or the pharmaceutical composition required to produce a desiredtherapeutic effect as may be judged by clinical trial results, modelanimal infection studies, and/or in vitro studies (e.g. in agar or brothmedia). The pharmaceutically effective amount depends on severalfactors, including but not limited to, the microorganism (e.g. bacteria)involved, characteristics of the subject (for example height, weight,sex, age and medical history), severity of infection and the particulartype of the antibacterial agent used. For prophylactic treatments, atherapeutically or prophylactically effective amount is that amountwhich would be effective in preventing a microbial (e.g. bacterial)infection.

The term “administration” or “administering” includes delivery of acomposition or one or more pharmaceutically active ingredients to asubject, including for example, by any appropriate methods, which servesto deliver the composition or its active ingredients or otherpharmaceutically active ingredients to the site of the infection. Themethod of administration may vary depending on various factors, such asfor example, the components of the pharmaceutical composition or thenature of the pharmaceutically active or inert ingredients, the site ofthe potential or actual infection, the microorganism involved, severityof the infection, age and physical condition of the subject and a like.Some non-limiting examples of ways to administer a composition or apharmaceutically active ingredient to a subject according to thisinvention includes oral, intravenous, topical, intrarespiratory,intraperitoneal, intramuscular, parenteral, sublingual, transdermal,intranasal, aerosol, intraocular, intratracheal, intrarectal, vaginal,gene gun, dermal patch, eye drop, ear drop or mouthwash. In case of apharmaceutical composition comprising more than one ingredient (activeor inert), one of way of administering such composition is by admixingthe ingredients (e.g. in the form of a suitable unit dosage form such astablet, capsule, solution, powder and a like) and then administering thedosage form. Alternatively, the ingredients may also be administeredseparately (simultaneously or one after the other) as long as theseingredients reach beneficial therapeutic levels such that thecomposition as a whole provides a synergistic and/or desired effect.

The term “growth” as used herein refers to a growth of one or moremicroorganisms and includes reproduction or population expansion of themicroorganism (e.g. bacteria). The term also includes maintenance ofon-going metabolic processes of a microorganism, including processesthat keep the microorganism alive.

The term, “effectiveness” as used herein refers to ability of atreatment or a composition or one or more pharmaceutically activeingredients to produce a desired biological effect in a subject. Forexample, the term “antibacterial effectiveness” of a composition or anantibacterial agent refers to the ability of the composition or theantibacterial agent to prevent or treat the microbial (e.g. bacterial)infection in a subject.

The term “synergistic” or “synergy” as used herein refers to theinteraction of two or more agents so that their combined effect isgreater than their individual effects.

The term “antibacterial agent” as used herein refers to any substance,compound or a combination of substances or a combination compoundscapable of: (i) inhibiting, reducing or preventing growth of bacteria;(ii) inhibiting or reducing ability of a bacteria to produce infectionin a subject; or (iii) inhibiting or reducing ability of bacteria tomultiply or remain infective in the environment. The term “antibacterialagent” also refers to compounds capable of decreasing infectivity orvirulence of bacteria.

The term “beta-lactam antibacterial agent” as used herein refers tocompounds with antibacterial properties and containing a beta-lactamnucleus in their molecular structure.

The term “beta-lactamase” as used herein refers to any enzyme or proteinor any other substance that breaks down a beta-lactam ring. The term“beta-lactamase” includes enzymes that are produced by bacteria and havethe ability to hydrolyze the beta-lactam ring in a beta-lactam compound,either partially or completely.

The term “beta-lactamase inhibitor” as used herein refers to a compoundcapable of inhibiting activity of one or more beta-lactamase enzymes,either partially or completely.

The term “pharmaceutically inert ingredient” or “carrier” or “excipient”refers to a compound or material used to facilitate administration of acompound, including for example, to increase the solubility of thecompound. Typical, non-limiting examples of solid carriers include,starch, lactose, dicalcium phosphate, sucrose, and kaolin and so on.Typical, non-limiting examples of liquid carriers include, sterilewater, saline, buffers, non-ionic surfactants, and edible oils such asoil, peanut and sesame oils and so on. In addition, various adjuvantscommonly used in the art may be included. These and other such compoundsare described in the literature, for example, in the Merck Index (Merck& Company, Rahway, N.J.). Considerations for inclusion of variouscomponents in pharmaceutical compositions are described, for example, inGilman et al. (Eds.) (1990); Goodman and Gilman's: The PharmacologicalBasis of Therapeutics, 8th Ed., Pergamon Press., which is incorporatedherein by reference in its entirety.

The term “subject” as used herein refers to vertebrate or invertebrate,including a mammal. The term “subject” includes human, animal, a bird, afish, or an amphibian. Typical, non-limiting examples of a “subject”includes humans, cats, dogs, horses, sheep, bovine cows, pigs, lambs,rats, mice and guinea pigs.

The term “pharmaceutically acceptable derivative” as used herein refersto and includes any pharmaceutically acceptable salt, pro-drugs,metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes,enantiomers or adducts of a compound described herein which, uponadministration to a subject, is capable of providing (directly orindirectly) the parent compound. For example, the term “antibacterialagent or a pharmaceutically acceptable derivative thereof” includes allderivatives of the antibacterial agent (such as salt, pro-drugs,metabolites, esters, ethers, hydrates, polymorphs, solvates, complexes,enantiomers or adducts) which, upon administration to a subject, iscapable of providing (directly or indirectly) the antibacterialcompound.

In general, the term “cation” includes Na, K, Mg, Ca, NH₄ ⁺, (CH₃CH₂)₃N⁺etc.

In one general aspect, there are provided compounds of Formula (I):

or a stereoisomer or a pharmaceutically acceptable salt thereof;

wherein:

R₁ is:

-   -   (a) hydrogen,    -   (b) (CO)_(n)—R₃,    -   (c) COOR₄, or    -   (d) COCH₂COR₃

n is 0, 1 or 2;

R₂ is:

-   -   (a) SO₃M,    -   (b) SO₂NH₂,    -   (c) PO₃M,    -   (d) CH₂COOM,    -   (e) CF₂COOM,    -   (f) CHFCOOM, or    -   (g) CF₃;

M is hydrogen or a cation;

R₃ is:

-   -   (a) hydrogen,    -   (b) C₁-C₆ alkyl optionally substituted with one or more        substituents independently selected from halogen, OR₅, CN,        COOR₅, CONR₆R₇, NR₆R₇, NR₅COR₈, NR₅CONR₆R₇, heterocyclyl,        heteroaryl, cycloalkyl or aryl,    -   (c) CN,    -   (d) NR₆R₇,    -   (e) CONR₆R₇,    -   (f) NHCONR₆R₇,    -   (g) aryl optionally substituted with one or more substituents        independently selected from C₁-C₆ alkyl, OR₅, NR₆R₇, halogen,        CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, or        NHCONR₆R₇,    -   (h) heterocyclyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, NHC(NH)NR₆R₇, or NHCONR₆R₇,    -   (i) heteroaryl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₆R₇,    -   (j) cycloalkyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₆R₇,    -   (k) cycloalkyl substituted with C₁-C₆ alkyl wherein C₁-C₆ alkyl        is further substituted with one or more substituents        independently selected from OR₅, NR₆R₇, halogen, CN, or CONR₆R₇,        or    -   (l) OR₈;

R₄ is:

-   -   (a) hydrogen,    -   (b) C₁-C₆ alkyl optionally substituted with one or more        substituents independently selected from halogen, OR₅, CN,        COOR₅, CONR₆R₇, NR₆R₇, NR₅COR₈, heterocyclyl, heteroaryl,        cycloalkyl or aryl,    -   (c) aryl optionally substituted with one or more substituents        independently selected from C₁-C₆ alkyl, OR₅, NR₆R₇, halogen,        CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, or        NHCONR₆R₇,    -   (d) heterocyclyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₆R₇,    -   (e) heteroaryl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₆R₇, or    -   (f) cycloalkyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₆R₇;

R₅ and R₈ are each independently:

-   -   (a) hydrogen, or    -   (b) C₁-C₆ alkyl optionally substituted with one or more        substituents independently selected from halogen, CN, CONR₆R₇,        NR₆R₇, heterocyclyl, heteroaryl, cycloalkyl or aryl;

R₆ and R₇ are each independently:

-   -   (a) hydrogen,    -   (b) C₁-C₆ alkyl optionally substituted with one or more        substituents independently selected from halogen, OR₅, CN,        COOR₅, CONR₅R₈, NR₅R₈, NR₅COR₈, heterocyclyl, heteroaryl,        cycloalkyl or aryl,    -   (c) aryl optionally substituted with one or more substituents        independently selected from C₁-C₆ alkyl, OR₅, NR₅R₈, halogen,        CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, or        NHCONR₅R₈,    -   (d) heterocyclyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₅R₈,    -   (e) heteroaryl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₅R₈,    -   (f) cycloalkyl optionally substituted with one or more        substituents independently selected from C₁-C₆ alkyl, OR₅,        NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl,        OSO₂-aryl, or NHCONR₅R₈, or    -   (g) R₆ and R₇ are joined together to form a four to seven member        ring.

Typical non-limiting examples of compounds according to the inventioninclude:

trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-{7-oxo-2-[N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]-oct-6-yloxy}-aceticacid;

trans-difluoro-{7-oxo-2-[N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]-oct-6-yloxy}-aceticacid;

trans-sulfuric acidmono-[2-hydrazinocarbonyl-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(amino-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(3-amino-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(4-amino-butanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-((2S)-2-amino-3-hydroxy-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[(2S,4S)-4-fluoro-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[(2S,4R)-4-methoxy-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(piperidin-4-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((S)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((S)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((R)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(piperazin-4-yl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-1-amino-1-phenyl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-3-amino-butanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(3-amino-2,2-dimethyl-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(1-aminomethyl-cyclopropan-1-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(2-amino-4-carboxamido-butanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(5-amino-pentanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-((2S)-2,6-diamino-hexanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-((2-aminoethoxy)-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[azetidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[pyrrolidin-1-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[((S)-3-pyrrolidin-2-yl)-propionyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[(RS)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[(2S,4R)-4-hydroxy-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[(2S,4S)-4-amino-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-[(2S,4S)-4-guanidino-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—[(RS)-3-piperidin-2-yl-propionyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-piperazin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((S)-morpholin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(3-oxo-3-piperazin-1-yl-propionyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′—((RS)-1-amino-1-pyridin-2-yl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

trans-sulfuric acidmono-[2-(N′-(2-amino-thiazol-4-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-(cyano-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt oftrans-N′-(7-oxo-6-sulfooxy-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylicacid)-hydrazinecarboxylic acid tert-butyl ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-(morpholin-4-yl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-(6-carboxamido-pyridin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-(morpholin-4-oxo-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-1-carbamoyl-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-[(2S,4S)-1-carbamoyl-4-fluoro-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-1-methanesulfonyl-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′-(cyano-dimethyl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-5-oxo-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;

or a stereoisomer or a pharmaceutically acceptable salt thereof.

In general, the compounds of the invention can be prepared according tothe following procedures (Scheme 1). A person of skills in the art wouldappreciate that the described methods can be varied or optimized furtherto provide the desired and related compounds. In the followingprocedures, all variables are as defined above.

As described in Scheme-1,trans-6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylic acid(1a), which is described in PCT International Publication No. WO2009/091856, was reacted with corresponding acid hydrazides in presenceof a suitable coupling agent such as EDC hydrochloride, ordicyclohexylcarbodiimide (DCC), in a solvent such as N,N dimethylformamide; N,N dimethyl acetamide; 1,4 dioxane; chloroform;dichloromethane; or dichloroethane at a temperature ranging from −15° C.to 60° C. for about 1 to 24 hours to obtain intermediate compound (1b).

The intermediate compound (1b) was subjected for hydrogenolysis inpresence of a suitable catalyst (e.g. 5% or 10% palladium on carbon, or20% palladium hydroxide on carbon) in presence of a suitable hydrogensource (such as hydrogen gas, ammonium formate, cyclohexene) in asuitable solvent (such as methanol, ethanol, methanol-dichloromethanemixture, or N,N dimethyl formamide-dichloromethane mixture) at atemperature ranging from about 25° C. to 60° C. for about 1 to 14 hoursto obtain intermediate compound (1c).

The intermediate compound (1c) was sulfonated by reacting it with asulfonating reagent (such as sulfur trioxide-pyridine complex, or sulfurtrioxide-N,N-dimethyl formamide complex) in a suitable solvent (such aspyridine, N,N-dimethyl formamide) at a temperature ranging from about25° C. to 90° C. for about 1 to 24 hours to obtain pyridine salt ofsulfonic acid which when treated with tetrabutyl ammonium sulfateprovided terabutylammonium salt of sulfonic acid as an intermediatecompound (1d).

Some compounds according to the invention were isolated as azwitterions, by treating intermediate compound (1d) with trifluoroaceticacid, in a suitable solvent (such as dichloromethane, chloroform, oracetonitrile) at a temperature ranging from about −10° C. to 40° C. forabout 1 to 14 hours, especially when R in intermediate compound (1d)contained tert-butoxycarbonyl protected amine function.

Some other compounds according to the invention were isolated as acorresponding sodium salt, by passing intermediate compound (1d) throughsodium form of Aberlite 200C resin in a tetrahydrofuran-water mixturefollowed by evaporation of the solvent under vacuum.

As described in Scheme-2, the hydroxyl intermediate (1c) obtained as perScheme-1, was subjected for alkylation with alkylating agent (such asethyl-bromoacetate, ethyl-fluoroacetate or ethyl-difluoroacetate) inpresence of a base (such as potassium carbonate, diisopropylethylamineor triethylamine) in a suitable solvent (such as N,N dimethyl formamide,N,N dimethyl acetamide or N-methylpyrrolidine) to provide O-alkylatedcompound (2d).

The compound (2d) was subjected for hydrolysis in presence of a base(such as lithium hydroxide or potassium hydroxide) in a suitable solvent(such as aqueous tetrahydrofuran, aquous dioxane) to provide compound ofFormula (I) after pH adjustment.

Optionally, if R₁ bears amine function protected with Boc group, then itwas removed in an additional step of deprotection by using a suitabledeprotecting agent (such as trifluoroacetic acid or HF pyridine) in asolvent (such as dichloromethane, chloroform or acetonitrile) to providecompound of Formula (I).

In some embodiments, there are provided pharmaceutical compositionscomprising a compound of Formula (I), or a stereoisomer or apharmaceutically acceptable salt thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of acompound of Formula (I) or a stereoisomer or a pharmaceuticallyacceptable salt thereof.

In some embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a compound of Formula (I) or a stereoisomer or apharmaceutically acceptable salt thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising a compound of Formula (I) or astereoisomer or a pharmaceutically acceptable salt thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising a compoundof Formula (I) or a stereoisomer or a pharmaceutically acceptable saltthereof.

In some embodiments, there are provided pharmaceutical compositionscomprising: (a) a compound of Formula (I), or a stereoisomer or apharmaceutically acceptable salt thereof, and (b) at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there are provided pharmaceuticalcompositions comprising: (a) a compound of Formula (I), or astereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In some other embodiments, there are provided pharmaceuticalcompositions comprising: (a) a compound of Formula (I), or astereoisomer or a pharmaceutically acceptable salt thereof, (b) at leastone beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof,and (c) at least one antibacterial agent or a pharmaceuticallyacceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, and (b) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one antibacterial agent or apharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) a compound of Formula (I), ora stereoisomer or a pharmaceutically acceptable salt thereof, (b) atleast one beta-lactamase inhibitor selected from sulbactam, tazobactam,clavulanic acid, or a pharmaceutically acceptable derivative thereof,and (c) at least one antibacterial agent or a pharmaceuticallyacceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a) acompound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof, and (c) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, and (b) at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, and (b) at least one antibacterial agent or apharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, and (b) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) a compound of Formula (I), or a stereoisomer or a pharmaceuticallyacceptable salt thereof, (b) at least one beta-lactamase inhibitorselected from sulbactam, tazobactam, clavulanic acid, or apharmaceutically acceptable derivative thereof, and (c) at least oneantibacterial agent or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of: (a) a compound of Formula (I), or a stereoisomer ora pharmaceutically acceptable salt thereof, (b) at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof, and (c) atleast one antibacterial agent or a pharmaceutically acceptablederivative thereof.

In some embodiments, there are provided pharmaceutical compositionscomprising: (a) trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, said methodcomprising administering to said subject a pharmaceutically effectiveamount of: (a) trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a)trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some embodiments, there are provided pharmaceutical compositionscomprising: (a) trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of:(a) trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, said methodcomprising administering to said subject a pharmaceutically effectiveamount of: (a) trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some other embodiments, there is provided a method for preventing ortreating bacterial infection in a subject, said method comprisingadministering to said subject a pharmaceutically effective amount of apharmaceutical composition comprising: (a) trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some embodiments, there is provided a method for preventing ortreating a bacterial infection in a subject, said infection being causedby bacteria producing one or more beta-lactamase enzymes, wherein themethod comprises administering to said subject a pharmaceuticallyeffective amount of a pharmaceutical composition comprising: (a)trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esteror a stereoisomer or a pharmaceutically acceptable salt thereof, and (b)sulbactam or a pharmaceutically acceptable derivative thereof.

In some embodiments, there are provided methods for increasingantibacterial effectiveness of a antibacterial agent in a subject, saidmethod comprising co-administering said antibacterial agent or apharmaceutically acceptable derivative thereof with a pharmaceuticallyeffective amount of a compound of Formula (I) or a stereoisomer or apharmaceutically acceptable salt thereof.

In some embodiments, the compositions and methods according to theinvention use compounds of Formula (I) or a stereoisomer or apharmaceutically acceptable salt thereof in combination with at leastone antibacterial agent or a pharmaceutically acceptable derivativethereof. A wide variety of antibacterial agents can be used. Typical,non-limiting examples of antibacterial agents include one or more ofantibacterial compounds generally classified as aminoglycosides,Ansamycins, Carbacephems, Cephalosporins, Cephamycins, Lincosamides,Lipopeptides, Macrolides, Monobactams, Nitrofurans, Penicillins,Polypeptides, Quinolones, Sulfonamides, Tetracyclines, Oxazolidinone andthe like.

Typical, non-limiting examples of Aminoglycoside antibacterial agentsinclude Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin,Tobramycin, Paromomycin, Arbekacin, Streptomycin, Apramycin and thelike.

Typical, non-limiting examples of Ansamycin antibacterial agents includeGeldanamycin, Herbimycin and the like.

Typical, non-limiting examples of Carbacephem antibacterial agentsinclude Loracarbef and the like.

Typical, non-limiting examples of Carbapenem antibacterial agentsinclude Ertapenem, Doripenem, Imipenem, Meropenem and the like.

Typical, non-limiting examples of Cephalosporin and Cephamycinantibacterial agents include Cefazolin, Cefacetrile, Cefadroxil,Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin,Cefatrizine, Cefazedone, Cefazaflur, Cefradine, Cefroxadine, Ceftezole,Cefaclor, Cefamandole, Cefminox, Cefonicid, Ceforanide, Cefotiam,Cefprozil, Cefbuperazone, Cefuroxime, Cefuzonam, Cephamycin, Cefoxitin,Cefotetan, Cefinetazole, Carbacephem, Cefixime, Ceftazidime,Ceftriaxone, Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet,Cefinenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole,Cefpiramide, Cefpodoxime, Cefsulodin, Cefteram, Ceftibuten, Ceftiolene,Ceftizoxime, Oxacephem, Cefepime, Cefozopran, Cefpirome, Cefquinome,Ceftobiprole, Ceftiofur, Cefquinome, Cefovecin, CXA-101, Ceftaroline,Ceftobiprole etc.

Typical, non-limiting examples of Lincosamide antibacterial agentsinclude Clindamycin, Lincomycin and the like.

Typical, non-limiting examples of Macrolide antibacterial agents includeAzithromycin, Clarithromycin, Dirithromycin, Erythromycin,Roxithromycin, Troleandomycin, Telithromycin, Spectinomycin,Solithromycin and the like.

Typical, non-limiting examples of Monobactam antibacterial agentsinclude Aztreonam and the like.

Typical, non-limiting examples of Nitrofuran antibacterial agentsinclude Furazolidone, Nitrofurantoin and the like.

Typical, non-limiting examples of Penicillin antibacterial agentsinclude Amoxicillin, Ampicillin, Azlocillin, Carbenicillin, Cloxacillin,Dicloxacillin, Flucloxacillin, Mezlocillin, Methicillin, Nafcillin,Oxacillin, Penicillin G, Penicillin V, Piperacillin, Temocillin,Ticarcillin and the like.

Typical, non-limiting examples of Polypeptide antibacterial agentsinclude Bacitracin, Colistin, Polymyxin B and the like.

Typical, non-limiting examples of Quinolone antibacterial agents includeCiprofloxacin, Enoxacin, Gatifloxacin, Levofloxacin, Lomefloxacin,Moxifloxacin, Nalidixic acid, Levonadifloxacin, Norfloxacin, Ofloxacin,Trovafloxacin, Grepafloxacin, Sparfloxacin, Temafloxacin and the like.

Typical, non-limiting examples of Sulfonamide antibacterial agentsinclude Mafenide, Sulfonamidochrysoidine, Sulfacetamide, Sulfadiazine,Sulfamethizole, Sulfamethoxazole, Sulfasalazine, Sulfisoxazole,Trimethoprim and the like.

Typical, non-limiting examples of Tetracycline antibacterial agentsinclude Demeclocycline, Doxycycline, Minocycline, Oxytetracycline,Tetracycline, Tigecycline and the like.

Typical, non-limiting examples of Oxazolidinone antibacterial agentsinclude Tedizolid, Linezolid, Ranbezolid, Torezolid, Radezolid etc.

The pharmaceutical compositions according to the invention may includeone or more pharmaceutically acceptable carriers or excipients or thelike, Typical, non-limiting examples of such carriers or excipientinclude mannitol, lactose, starch, magnesium stearate, sodiumsaccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin,sucrose, magnesium carbonate, wetting agents, emulsifying agents,solubilizing agents, pH buffering agents, lubricants, stabilizingagents, binding agents etc.

The pharmaceutical compositions according to this invention can exist invarious forms. In some embodiments, the pharmaceutical composition is inthe form of a powder or a solution. In some other embodiments, thepharmaceutical compositions according to the invention are in the formof a powder that can be reconstituted by addition of a compatiblereconstitution diluent prior to parenteral administration. Non-limitingexample of such a compatible reconstitution diluent includes water.

In some other embodiments, the pharmaceutical compositions according tothe invention are in the form of a frozen composition that can bediluted with a compatible diluent prior to parenteral administration.

In some other embodiments, the pharmaceutical compositions according tothe invention are in the form ready to use for parenteraladministration.

In the methods according to the invention, the pharmaceuticalcomposition and/or other pharmaceutically active ingredients disclosedherein may be administered by any appropriate method, which serves todeliver the composition or its constituents or the active ingredients tothe desired site. The method of administration can vary depending onvarious factors, such as for example, the components of thepharmaceutical composition and nature of the active ingredients, thesite of the potential or actual infection, the microorganism (e.g.bacteria) involved, severity of infection, age and physical condition ofthe subject. Some non-limiting examples of administering the compositionto a subject according to this invention include oral, intravenous,topical, intrarespiratory, intraperitoneal, intramuscular, parenteral,sublingual, transdermal, intranasal, aerosol, intraocular,intratracheal, intrarectal, vaginal, gene gun, dermal patch, eye drop,ear drop or mouthwash.

The compositions according to the invention can be formulated intovarious dosage forms wherein the active ingredients and/or excipientsmay be present either together (e.g. as an admixture) or as separatecomponents. When the various ingredients in the composition areformulated as a mixture, such composition can be delivered byadministering such a mixture. The composition or dosage form wherein theingredients do not come as a mixture, but come as separate components,such composition/dosage form may be administered in several ways. In onepossible way, the ingredients may be mixed in the desired proportionsand the mixture is then administered as required. Alternatively, thecomponents or the ingredients (active or inert) may be separatelyadministered (simultaneously or one after the other) in appropriateproportion so as to achieve the same or equivalent therapeutic level oreffect as would have been achieved by administration of the equivalentmixture.

Similarly, in the methods according to the invention, the activeingredients disclosed herein may be administered to a subject in severalways depending on the requirements. In some embodiments, the activeingredients are admixed in appropriate amounts and then the admixture isadministered to a subject. In some other embodiments, the activeingredients are administered separately. Since the inventioncontemplates that the active ingredients agents may be administeredseparately, the invention further provides for combining separatepharmaceutical compositions in kit form. The kit may comprise one ormore separate pharmaceutical compositions, each comprising one or moreactive ingredients. Each of such separate compositions may be present ina separate container such as a bottle, vial, syringes, boxes, bags, andthe like. Typically, the kit comprises directions for the administrationof the separate components. The kit form is particularly advantageouswhen the separate components are preferably administered in differentdosage forms (e.g., oral and parenteral) ore are administered atdifferent dosage intervals. When the active ingredients are administeredseparately, they may be administered simultaneously or sequentially.

The pharmaceutical composition or the active ingredients according tothe present invention may be formulated into a variety of dosage forms.Typical, non-limiting examples of dosage forms include solid,semi-solid, liquid and aerosol dosage forms; such as tablets, capsules,powders, solutions, suspensions, suppositories, aerosols, granules,emulsions, syrups, elixirs and a like.

In general, the pharmaceutical compositions and method disclosed hereinare useful in preventing or treating bacterial infections.Advantageously, the compositions and methods disclosed herein are alsoeffective in preventing or treating infections caused by bacteria thatare considered be less or not susceptible to one or more of knownantibacterial agents or their known compositions. Some non-limitingexamples of such bacteria known to have developed resistance to variousantibacterial agents include Acinetobacter, E. coli, Pseudomonasaeruginosa, Staphylococcus aureus, Enterobacter, Klebsiella, Citrobacterand a like. Other non-limiting examples of infections that may beprevented or treated using the compositions and/or methods of theinvention include: skin and soft tissue infections, febrile neutropenia,urinary tract infection, intraabdominal infections, respiratory tractinfections, pneumonia (nosocomial), bacteremia meningitis, surgical,infections etc.

Surprisingly, the compounds, compositions and methods according to theinvention are also effective in preventing or treating bacterialinfections that are caused by bacteria producing one or morebeta-lactamase enzymes. The ability of compositions and methodsaccording to the present invention to treat such resistant bacteria withtypical beta-lactam antibiotics represents a significant improvement inthe art.

In general, the compounds of Formula (I) or a stereoisomer orpharmaceutically acceptable salt thereof according to invention are alsouseful in increasing antibacterial effectiveness of a antibacterialagent in a subject. The antibacterial effectiveness of one or moreantibacterial agents may increased, for example, by co-administeringsaid antibacterial agent or a pharmaceutically acceptable derivativethereof with a pharmaceutically effective amount of a compound ofFormula (I) or a stereoisomer or a pharmaceutically acceptable saltthereof according to the invention.

It will be readily apparent to one skilled in the art that varyingsubstitutions and modifications may be made to the invention disclosedherein without departing from the scope and spirit of the invention. Forexample, those skilled in the art will recognize that the invention maybe practiced using a variety of different compounds within the describedgeneric descriptions.

EXAMPLES

The following examples illustrate the embodiments of the invention thatare presently best known. However, it is to be understood that thefollowing are only exemplary or illustrative of the application of theprinciples of the present invention. Numerous modifications andalternative compositions, methods, and systems may be devised by thoseskilled in the art without departing from the spirit and scope of thepresent invention. The appended claims are intended to cover suchmodifications and arrangements. Thus, while the present invention hasbeen described above with particularity, the following examples providefurther detail in connection with what are presently deemed to be themost practical and preferred embodiments of the invention.

Example-1 trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

Step-1: Preparation oftrans-2-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tert-butyl ester

To a clear solution oftrans-6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylic acid(15 gm, 0.054 mol) in N,N-dimethyl formamide (150 ml), was added EDChydrochloride (15.57 gm, 0.082 mol) followed by HOBt (11.0 gm, 0.082mol) at about 25° C. to 35° C. under stirring. The reaction mixture wasstirred for 15 minutes and a solution of(S)—N-tert-butoxycarbonyl-pyrrolidin-2-carboxylic acid hydrazide (14.93gm, 0.065 mol) dissolved in N,N-dimethyl formamide (75 ml), followed byN,N-di-isopropyl ethylamine (28.4 ml, 0.163 mol) were added. Thereaction mixture was stirred at a temperature between 25° C. to 35° C.for 16 hours. The reaction mixture was poured under stirring into 10%aqueous citric acid solution (2250 ml). The resulting mixture wasextracted with diethyl ether (1000 ml×3). Combined organic layer waswashed with water (1000 ml) followed by brine solution (500 ml) anddried over sodium sulfate. Concentration of organic layer under vacuumafforded the crude residue in 13 gm quantity. The residue was purifiedusing silica gel column chromatography to provide the product(trans-2-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tert-butyl ester) in 6.3 gm quantity as a white powder.

Analysis: MS (ES+) C₂₄H₃₃N₅O₆=488.1 (M+1);

H¹NMR (DMSO-d₆)=9.86 (br d, 1H), 9.75 (br d, 1H), 7.34-7.44 (m, 5H),4.92 (dd, 2H), 4.07-4.10 (m, 1H), 3.78-3.82 (m, 1H), 3.68 (br d, 1H),3.20-3.25 (m, 3H), 2.87 (br d, 1H), 1.62-2.10 (m, 8H), 1.34 (s, 9H).

Step-2: Preparation oftrans-2-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tert-butyl ester

To a clear solution of step-1 product (3.0 gm, 6.15 mmol) in methanol(30 ml) was added 10% palladium on carbon (300 mg). The suspension wasstirred under atmospheric hydrogen pressure at a temperature of about30° C. for 2 hours. The catalyst was filtered over a celite bed andcatalyst-containing bed was washed with additional methanol (10 ml) anddichloromethane (10 ml). The filtrate was concentrated in vacuum toprovide a white powder, which was triturated with diethyl ether toprovidetrans-2-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tert-butyl ester as a white powder in 2.00 gm quantity in 82%yield.

Analysis: MS (ES⁺) C₁₇H₂₇N₅O₆=398.0 (M+1);

H¹NMR (DMSO-d₆)=9.82 (d, 1H), 9.70-9.80 (m, 2H), 4.08-4.15 (m, 1H),3.4.0-3.78 (m, 1H), 3.59 (br s, 1H), 3.17-3.40 (m, 3H), 2.97 (br d, 1H),1.55-2.15 (m, 8H), 1.35 (s, 9H).

Step-3: Preparation of tetrabutylammonium salt oftrans-2-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tetr-butyl ester

The product obtained in step-2 (2.00 gm, 5.03 mmol) was dissolved inpyridine (40 ml) and to the clear solution was added pyridine sulfurtrioxide complex (4.03 gm, 25.18 mmol). The suspension was stirred at atemperature 25° C. to 35° C. for overnight. The suspension was filteredand the solids were washed with dichloromethane (25 ml×2). The filtratewas evaporated under vacuum and the residue was stirred in 0.5 N aqueouspotassium dihydrogen phosphate solution (200 ml) for 0.5 hour. Thesolution was washed with ethyl acetate (100 ml×4) and layers wereseparated. To the aqueous layer was added tetrabutylammonium sulphate(1.71 gm, 5.03 mmol) and stirred for four hours at about 25° C. Themixture was extracted with dichloromethane (100 ml×2). The combinedorganic extract was washed with brine (50 ml) and dried on sodiumsulfate and evaporated under vacuum to provide solid, that wastriturated with diethyl ether and filtered to provide white powder as astep-3 product (tetrabutylammonium salt oftrans-2-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(S)-pyrrolidin-1-carboxylicacid tetr-butyl ester), in 3.0 gm quantity (83% yield).

Analysis: MS (ES−) C₁₇H₂₆N₅O₉S.N(C₄H₉)₄ as a salt=476.0 (M−1) as a freesulfonic acid;

H¹NMR (CDCl₃)=9.13 (br s, 1H), 8.49 (br s, 1H), 4.35 (br s, 2H), 3.98(d, 1H), 3.24-3.50 (m, 10H), 3.13 (br d, 1H), 2.35 (dd, 2H), 2.16 (br s,2H), 1.91-2.01 (m, 4H), 1.61-1.70 (m, 10H), 1.40-1.48 (m, 17H),0.98-1.02 (m, 12H).

Step-4: trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

To the powder obtained in step-3 (3.0 gm, 4.17 mmol) was added, asolution of trifluoroacetic acid (7 ml) in dichloromethane (7 ml) slowlyby syringe at −5° C. over a period of 5 minutes. The mixture wasmaintained under stirring for 1 hr. Solvents were removed below 40° C.under high vacuum to provide a residue, which was triturated withdiethyl ether (50 ml×5) and each time diethyl ether was decanted. Theobtained white solid was further triturated with acetonitrile (100ml×2). The resultant solid was stirred in dichloromethane (100 nil) andthe suspension was filtered. The solid was dried under vacuum to providetitle compound of the invention (trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester)in 1.2 gm quantity (59% yield).

Analysis: MS (ES−) C₁₂H₁₉N₅O₇S=376.2 (M−1) as a free sulfonic acid;

H¹NMR (DMSO-d₆)=10.39 (br s, 1H), 10.15 (s, 1H), 8.96 (br s, 2H), 4.19(t, 1H), 4.03 (br s, 1H), 3.86 (d, 1H), 3.16-3.25 (m, 3H), 3.02 (br d,1H), 2.27-2.33 (m, 1H), 1.92-2.23 (m, 1H), 1.84-1.90 (m, 4H), 1.69-1.75(m, 1H), 1.54-1.62 (m, 1H).

Example-2 trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

Step-1: Preparation oftrans-3-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-1 of Example-1 above, and byusingtrans-6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylic acid(25 gm, 0.084 mol), N,N-dimethyl formamide (625 ml), EDC hydrochloride(24 gm, 0.126 mol), HOBt (16.96 gm, 0.126 mol),(R)—N-tert-butoxycarbonyl-piperidin-3-carboxylic acid hydrazide (21.40gm, 0.088 mol) to provide the title compound in 17.0 gm quantity, 41%yield as a white solid.

Analysis: MS (ES+) C₂₅H₃₅N₅O₆=502.1 (M+1);

H¹NMR (CDCl₃)=8.40 (br s, 1H), 7.34-7.44 (m, 5H), 5.05 (d, 1H), 4.90 (d,1H), 4.00 (br d, 1H), 3.82 (br s, 1H), 3.30 (br s, 1H), 3.16-3.21 (m,1H), 3.06 (br d, 1H), 2.42 (br s, 1H), 2.29-2.34 (m, 1H), 1.18-2.02 (m,4H), 1.60-1.75 (m, 4H), 1.45-1.55 (m, 2H), 1.44 (s, 9H).

Step-2: Preparation oftrans-3-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-2 of Example-1 above, and byusingtrans-3-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester (16.5 gm, 0.033 mol), methanol (170 ml) and 10%palladium on carbon (3.5 gm) to provide the title compound in 13.5 gmquantity as a pale pink solid and it was used for the next reactionimmediately.

Analysis: MS (ES+) C₁₈H₂₉N₅O₆=411.1 (M+1);

Step-3: Preparation of tetrabutylammonium salt oftrans-3-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-3 of Example-1 above, and byusingtrans-3-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester (13.5 gm, 0.033 mol), pyridine (70 ml) andpyridine sulfur trioxide complex (26.11 gm, 0.164 mol), 0.5 N aqueouspotassium dihydrogen phosphate solution (400 ml) and tetrabutylammoniumsulphate (9.74 gm, 0.033 mol) to provide the title compound in 25 gmquantity as a yellowish solid, in quantitative yield.

Analysis: MS (ES−) C₁₈H₂₈N₅O₉S.N(C₄H₉)₄ as a salt=490.0 (M−1) as a freesulfonic acid;

Step-4: trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

By using the procedure described in Step-4 of Example-1 above, and byusing tetrabutylammonium salt oftrans-3-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester (24 gm, 0.032 mmol), dichloromethane (60 ml) andtrifluoroacetic acid (60 nil) to provide the title compound in 10 gmquantity as a white solid, in 79% yield.

Analysis: MS (ES−)=C₁₃H₂₁N₅O₇S=390.2 (M−1) as a free sulfonic acid;

H¹NMR (DMSO-d₆)=9.97 (d, 2H), 8.32 (br s, 2H), 4.00 (br s, 1H), 3.81 (d,1H), 3.10-3.22 (m, 3H), 2.97-3.02 (m, 2H), 2.86-2.91 (m, 1H), 2.65-2.66(m, 1H), 1.97-2.03 (m, 1H), 1.57-1.88 (m, 7H).

[α]_(D) ²⁵=−32.6°, (c 0.5, water).

Example-3 trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

Step-1: Preparation oftrans-3-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-1 of Example-1, and by usingtrans-6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylic acid(15.7 gm, 0.057 mol), N,N-dimethyl formamide (390 ml), EDC hydrochloride(16.24 gm, 0.085 mol), HOBt (11.48 gm, 0.085 mol),(R)—N-tert-butoxycarbonyl-pyrrolidin-3-carboxylic acid hydrazide (13.7gm, 0.06 mol) to provide the title compound in 11.94 gm quantity, 43%yield as a white solid.

Analysis: MS (ES+) C₂₄H₃₃N₅O₆=488.2 (M+1);

H¹NMR (CDCl₃), D₂O exchange=7.30-7.39 (m, 5H), 4.85 (s, 2H), 3.77 (d,1H), 3.68 (br s, 1H), 3.39-3.41 (m, 1H), 3.17-3.26 (m, 3H), 3.01 (d,1H), 2.90-2.92 (m, 2H), 1.97-2.03 (m, 2H), 1.79-1.89 (m, 2H), 1.66-1.70(m, 1H), 1.55-1.57 (m, 1H), 1.32 (s, 9H).

Step-2: Preparation oftrans-3-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-2 of Example-1, and by usingtrans-3-[N′-(6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester (11.5 gm, 0.024 mol), methanol (115 ml) and 10%palladium on carbon (3.0 gm) to provide the title compound in 9.5 gmquantity as a pale brown solid and it was used for the next reactionimmediately.

Analysis: MS (ES+) C₁₇H₂₇N₅O₆=398.2 (M+1);

Step-3: Preparation of tetrabutylammonium salt oftrans-3-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester

By using the procedure described in Step-3 of Example-1, and by usingtrans-3-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester (9.5 gm, 0.024 mol), pyridine (95 ml) and pyridinesulfur trioxide complex (19.08 gm, 0.12 mol), 0.5 N aqueous potassiumdihydrogen phosphate solution (300 ml) and tetrabutylammonium sulphate(8.15 gm, 0.024 mol) to provide the title compound in 15.3 gm quantityas a yellowish solid, in 87% yield.

Analysis: MS (ES−) C₁₇H₂₆N₅O₉S.N(C₄H₉)₄ as a salt=476.1 (M−1) as a freesulfonic acid;

H¹NMR (DMSO-d₆)=9.82 (d, 2H), 3.97 (br s, 1H), 3.79 (d, 1H), 3.42-3.44(m, 1H), 3.00-3.18 (m, 10H), 2.65-2.97 (m, 2H), 1.98-2.01 (m, 2H),1.74-1.83 (m, 2H), 1.63-1.72 (m, 1H), 1.38-1.55 (m, 9H), 1.33 (s, 9H),1.24-1.28 (m. 8H), 0.91-0.99 (m, 12H).

Step-4: trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

By using the procedure described in Step-4 of Example-1, and by usingtetrabutylammonium salt oftrans-3-[N′-(6-sulfooxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-pyrrolidin-1-carboxylicacid tert-butyl ester (15 gm, 0.021 mmol), dichloromethane (37 ml) andtrifluoroacetic acid (37 nil) to provide the title compound in 7.7 gmquantity as a white solid.

Analysis: MS (ES−)=C₁₂H₁₉N₅O₇S=376.1 (M−1) as a free sulfonic acid;

H¹NMR (DMSO-d₆)=10.04 (s, 1H), 9.96 (s, 1H), 8.79 (br s, 1H), 8.68 (brs, 1H), 4.00 (br s, 1H), 3.82 (d, 1H), 3.18-3.32 (m, 4H), 3.08-3.12 (m,1H), 3.00 (br d, 1H), 2.05-2.29 (m, 1H), 1.96-2.05 (m, 2H), 1.84-1.87(m, 1H), 1.69-1.73 (m, 1H), 1.56-1.67 (m, 1H).

[α]_(D) ²⁵=−44.2°, (c 0.5, water).

Example-4trans-{7-oxo-2-[N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]-oct-6-yloxy}-aceticacid

Step-1: Preparation oftrans-3-{N′-(6-ethoxycarbonylmethoxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl}-(R)-piperidin-1-carboxylicacid tert-butyl ester

The intermediate compoundtrans-3-[N′-(6-hydroxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl]-(R)-piperidin-1-carboxylicacid tert-butyl ester (4.0 gm, 9.73 mmol), obtained in Step-2 ofExample-2) was dissolved in DMF (12 ml) and to the clear solution wasadded potassium carbonate (1.61 gm, 11.6 mmol) followed by ethyl bromoacetate (1.2 ml, 10.0 mmol) under stirring and the suspension wasstirred for 18 hours at about 25° C. The reaction was monitored by TLC.DMF was evaporated under vacuum to provide a residue. The residue waspurified by silica gel column chromatography to provide titled Step-1intermediate compound in 2.6 gm quantity as a solid in 53.7% yield.

Analysis: MS (+)=C₂₂H₃₅N₅O₈=498.1 (M+1);

H¹NMR (CDCl₃)=8.45 (br s, 2H), 4.58 (s, 2H), 4.19-4.27 (m, 2H),4.02-4.12 (m, 2H), 3.25 (br d, 1H), 3.15 (br d, 1H), 2.38 (br s, 1H),2.35 (dd, 1H), 2.15-2.20 (m, 1H), 1.79-2.02 (m, 4H), 1.67-1.77 (m, 4H),1.44-1.51 (m, 11H), 1.28 (t, 3H).

Step-2: Preparation oftrans-3-{N′-(6-carboxymethoxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl}-(R)-piperidin-1-carboxylicacid tert-butyl ester

To a clear solution oftrans-3-{N′-(6-ethoxycarbonylmethoxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl}-(R)-piperidin-1-carboxylicacid tert-butyl ester (600 mg, 1.20 mmol) in tetrahydrofuran (32 ml) andwater (12 ml) was added lithium hydroxide (43.2 mg, 1.8 mmol) at 0° C.The reaction mixture was stirred for 3 hours and was neutralized to pH 6by addition of aqueous 1 N potassium hydrogen sulfate. It was exactedwith ethyl acetate (3×25 ml). Layers were separated and aqueous layerwas acidified with 1 N potassium hydrogen sulfate to pH 1 and extractedwith ethyl acetate (3×25 ml). The Organic layer was dried over sodiumsulfate and evaporated to dryness under vacuum to provide 160 mg oftilted intermediate as a solid in 27% yield.

Analysis: MS (ES+)=C₂₀H₃₁N₅O₈=470.1 (M+1)

H¹NMR (CDCl₃)=8.40 (br s, 2H), 4.67 (d, 1H), 4.52 (d, 1H), 4.07-4.14 (m,2H), 3.95 (br s, 1H), 3.43 (br d, 1H), 3.19 (br d, 1H), 2.47 (br s, 1H),2.39 (dd, 1H), 2.09-2.13 (m, 2H), 1.77-2.00 (m, 4H), 1.68-1.77 (m, 2H),1.45-1.51 (m, 11H).

Step-3:trans-{7-oxo-2-[N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]-oct-6-yloxy}-aceticacid

To a clear solution oftrans-3-{N′-(6-carboxymethoxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carbonyl)-hydrazinocarbonyl}-(R)-piperidin-1-carboxylicacid tert-butyl ester (150 mg, 0.32 mmol) in dichloromethane (2 ml) wasadded trifluoroacetic acid under stirring at −10° C. The reactionmixture was stirred for about 1 hour at −10° C. and the solvents wereevaporated under vacuum to provide a residue. The residue was trituratedsuccessively with diethyl ether (25 ml) and acetonitrile (25 ml) andsolvents were decanted to provide solid that was dried under vacuum toprovide 59 mg of titled compound in 50% yield.

Analysis: MS (ES−)=C₁₅H₂₃N₅O₆=368.0 (M−1)

H¹NMR (DMSO-d₆)=9.97 (br s, 2H), 4.48 (d, 1H), 4.29 (d, 1H), 3.91 (s,1H), 3.83 (d, 1H), 3.36 (q, 1H), 3.11-3.21 (m, 4H), 2.84-3.01 (m, 3H),2.66 (br s, 1H), 1.90-2.05 (m, 3H), 1.69-1.76 (m, 2H), 1.59-1.66 (m,3H).

Example-5trans-difluoro-{7-oxo-2-[N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1]-oct-6-yloxy}-aceticacid

By using procedure the described in Example 4 and by using ethyl-bromodifluoroacetate (2.0 gm, 10.0 mmol) in the place of ethyl bromo acetate,the titled compound was prepared in 30 mg quantity as a solid.

Analysis: MS (ES+)=C₁₅H₂₁F₂N₅O₆=406.2 (M+1)

H¹NMR (DMSO-d₆)=10.99 (d, 2H), 8.59 (br s, 2H), 3.89-4.00 (m, 2H),3.13-3.31 (m, 4H), 2.95-3.07 (m, 2H), 2.81-2.88 (m, 1H), 2.62-2.78 (m,1H), 1.97-2.05 (m, 1H), 1-84-1.95 (m, 1H), 1.72-1.79 (m, 2H), 1.59-1.64(m, 3H).

Compounds 6 to 42 (Table 1) were prepared using the procedure describedas in Example-1 and using corresponding R₁CONHNH₂, in place of(S)—N-tert-butoxycarbonyl-pyrrolidin-2-carboxylic acid hydrazide.

TABLE 1 Example Acid hydrazide Mass (ES-1) as No. (R₁CONHNH₂) R₁ H¹ NMR(DMSO-d₆) free acid (MF)  6. t-Boc—NHNH₂ H 11.05 (br s, 1H), 9.39 (br279.1 s, 2H), 4.04 (d, 1H), (C₇H₁₂N₄O₆S) 3.92 (d, 1H), 3.04 (br d, 1H),2.48 (d, 1H), 1.99- 2.05 (m, 1H), 1.86-1.90 (m, 1H), 1.63-1.77 (m, 2H). 7. t-Boc—HNCH₂—CONHNH₂ H₂NCH₂—CO— 10.20 (bs, 1H), 8.20 (br 336.2 s,3H), 4.01 (br s, 1H), (C₉H₁₅N₅O₇S) 3.86 (br d, 1H), 3.61 (s, 2H), 2.99(d, 1H), 1.97- 2.05 (m, 1H), 1.78-1.88 (m, 1H), 1.68-1.72 (m, 1H),1.54-1.67 (m, 2H).  8. t-Boc—HNCH₂CH₂—CONHNH₂ H₂NCH₂CH₂—CO— 9.34 (d,2H), 7.66 (br s, 2H), 350.2 4.00 (br d, 1H), 3.84 (d, 1H), (C₁₀H₁₆N₅O₇S)3.16 (d, 1H), 2.92-3.00 (m, 3H), 2.43-2.53 (m, 2H), 1.85- 2.05 (m, 1H),1.74-1.75 (m, 1H), 1.51-1.73 (m, 2H).  9. t-Boc—HN—(CH₂)₃—CONHNH₂H₂N(CH₂)₃—CO— 9.87 (s, 1H), 9.77 (s, 1H), 363.9 7.63 (br s, 3H), 4.00(br s, (C₁₁H₁₉N₅O₇S) 1H), 3.86 (d, 1H), 3.16 (d, 1H), 2.76-2.73 (m, 2H),2.20 (t, 2H), 1.97-2.01 (m, 1H), 1.51-1.84 (m, 6H). 10.

10.33 (s, 1H), 10.09 (s, 1H), 8.19 (br s, 3H), 5.48 (br s, 1H), 4.02 (brs, 1H), 3.86 (d, 1H), 3.79 (d, 1H), 3.64- 3.68 (m, 1H), 3.21 (d, 1H),3.02 (d, 1H), 1.98- 2.05 (m, 1H), 1.82-1.88 (m, 1H), 1.68-1.75 (m, 1H),1.54-1.62 (m, 1H). 366.2 (C₁₀H₁₇N₅O₈S) 11.

10.46 (s, 1H), 10.20 (s, 1H), 9.73 (br s, 1H), 9.15 (br s, 1H), 5.44 (brs, 1H), 5.31- 4.45 (d, 1H), 3.99 (s, 1H), 3.87 (d, 1H), 3.61 (dd, 2H),3.28-3.42 (m, 1H), 3.02- 3.12 (m, 2H), 2.60-2.82 (m, 1H), 2.30-2.42 (m,1H), 1.99-2.04 (m, 1H), 1.80- 1.90 (m, 1H), 1.58-1.74 (m, 2H). 393.9(C₁₂H₁₈N₅FO₇S) 12.

10.41 (s, 1H), 10.19 (s, 1H), 9.59 (br s, 1H), 8.97 (br s, 1H),4.19-4.24 (m, 1H), 4.13 (br s, 1H), 4.02 (br s, 1H), 3.87 (d, 1H), 3.38(s, 3H), 3.16-3.33 (m, 3H), 3.02 (br d, 1H), 1.57-2.05 (m, 6 H). 406.2(C₁₃H₂₁N₅O₈S) 13.

9.82 (d, 1H), 8.41 (br d, 1H), 8.19 (br d, 1H), 3.99 (br s, 1H), 3.80(d, 1H), 3.18-3.39 (m, 5H), 2.90-3.00 (m, 3H), 1.97-2.03 (m, 1H), 1.75-1.84 (m, 2H), 1.67-1.71 (m, 3H), 1.57-1.62 (m, 2H). 390.3 (C₁₃H₂₁N₅O₇S)14.

9.99 (d, 2H), 8.40 (br s, 2H), 4.00 (br s, 1H), 3.81 (d, 1H), 3.10-3.21(m, 4H), 2.91-3.01 (m, 3H), 2.65-2.66 (m, 1H), 1.97- 2.05 (m, 1H), 1.54-1.88 (m, 7H). 389.9 (C₁₃H₂₁N₅O₇S) 15.

9.96 (d, 2H), 8.39 (br s, 2H), 4.00 (br s, 1H), 3.81 (d, 1H), 3.09-3.17(m, 3H), 2.97-3.02 (m, 1H), 2.87-2.92 (m, 1H), 2.60- 2.65 (m, 1H),1.97-2.02 (m, 1H), 1.58-1.84 (m, 8H). 390.2 (C₁₃H₂₁N₅O₇S) 16.

10.29 (d, 1H), 10.16 (d, 1H), 8.90-9.03 (m, 1H), 8.70-8.78 (m, 1H), 4.02(br s, 1H), 3.82- 3.87 (m, 2H), 3.12-3.22 (m, 2H), 2.93-3.03 (m, 2H),1.86- 2.10 (m, 2H), 1.24-1.72 (m, 8H). 390.2 (C₁₃H₂₁N₅O₇S) 17.

10.30 (s, 1H), 10.14 (s, 1H), 9.00 (br d, 1H), 8.70-8.75 (m, 1H), 4.02(br s, 1H), 3.81-3.87 (m, 2H), 3.17-3.21 (m, 2H), 2.93-3.03 (m, 2H),2.10 (br d, 1H),1.98-2.05 (m, 1H), 1.85- 1.92 (m, 1H), 1.69-1.77 (m,3H), 1.46-1.66 (m, 4H). 390.3 (C₁₃H₂₁N₅O₇S) 18.

10.27 (s, 1H), 10.17 (s, 1H), 8.93 (br d, 1H), 8.76-8.78 (m, 1H), 4.02(br s, 1H), 3.79-3.86 (m, 2H), 3.18-3.23 (m, 2H), 2.93-3.02 (m, 2H),2.14 (br d, 1H), 1.97-2.05 (m, 1H), 1.83- 1.93 (m, 1H), 1.46-1.77 (m,7H). 390.3 (C₁₃H₂₁N₅O₇S) 19.

10.00 (d, 1H), 9.68 (br s, 1H), 4.01 (br s, 1H), 3.83 (d, 1H), 3.42 (s,1H), 3.12-3.21 (m, 6H), 2.93-3.02 (m, 4H), 1.98- 2.05 (m, 1H), 1.84-1.92(m, 1H), 1.68-1.72 (m, 1H), 1.54- 1.62 (m, 1H). 404.9 (C₁₃H₂₂N₆O₇S) 20.

10.44 (d, 1H), 10.18 (d, 1H), 8.67 (br d, 3H), 7.43-7.55 (m, 5H), 4.98(br s, 1H), 4.01 (s, 1H), 3.83 (br d, 1H), 3.19 (d, 1H), 3.00 (br d,1H), 1.85- 2.05 (m, 2H), 1.59-1.72 (m, 2H). 411.9 (C₁₅H₁₉N₅O₇S) 21.(RS)-t-Boc—HNCH(CH₃)CH₂—CONHNH₂ (RS)-H₂NCH(CH₃)CH₂—CO— 10.00 (s, 1H),9.95 (d, 1H), 364.1 7.74 (br s, 3H), 4.01 (br s, (C₁₁H₁₉N₅O₇S) 1H), 3.83(d, 1H), 3.53-3.48 (m, 1H), 3.12-3.19 (m, 1H), 3.00 (br d, 1H),2.36-2.42 (m, 1H), 1.98-2.06 (m, 1H), 1.78-1.87 (m, 1H), 1.66- 1.76 (m,1H), 1.54-1.62 (m, 2H), 1.19 (d, 3H) 22.

9.92 (S, 1H), 9.82 (S, 1H), 7.71 (br s, 3H), 4.01 (br s, 1H), 3.84 (d,1H), 3.21 (d, 1H), 3.01 (br d, 1H), 2.85-2.92 (m, 2H), 1.98- 2.04 (m,1H), 1.85-1.87 (m, 1H), 1.69-1.73 (m, 1H), 1.57- 1.60 (m, 1H), 1.22 (d,6 H). 378.2 (C₁₂H₂₁N₅O₇S) 23.

9.82 (s, 1H), 7.76 (br s, 3H), 4.00 (br s, 1H), 3.81 (d, 1H), 3.22 (d,1H), 2.00 (d, 2H), 2.88 (d, 1H), 1.97-2.05 (m, 1H), 1.74-1.85 (m, 1H),1.16-1.73 (m, 1H), 1.54-1.61 (m, 1H), 1.27 (t, 2H) 1.01-1.08 (m, 2H).376.2 (C₁₂H₁₉N₅O₇S) 24.

10.37 (s, 1H), 10.16 (s, 1H), 8.24 (br s, 3H), 7.39 (br s, 1H), 6.95 (brs, 1H), 4.02 (br s, 1H), 3.86 (d, 1H), 3.19 (d, 1H), 3.02 (br d, 1H),2.20-2.34 (m, 2H), 1.92- 2.05 (m, 4H), 1.67-1.79 (m, 1H), 1.55-1.63 (m,1H). 407.2 (C₁₂H₂₀N₆O₈S) 25. t-Boc—HN—(CH₂)₄—CONHNH₂ H₂N(CH₂)₄—CO— 9.18(s, 1H), 9.70 (s, 1H), 378.2 7.58 (br s, 3H), 3.99 (br s, (C₁₂H₂₁N₅O₇S)1H), 3.80 (d, 1H), 3.21 (d, 1H), 3.99 (b rd, 1H), 2.76- (br s, 2H),2.15-2.20 (m, 1H), 1.97-2.01 (m, 1H), 1.82- 1.85 (m, 1H), 1.67-1.73 (m,1H), 1.55-1.62 (m, 6H). 26.

10.16 (s, 1H), 7.86 (br s, 6H), 4.03 (br s, 1H), 3.88 (d, 1H), 3.77 (t,1H), 3.16 (d, 1H), 3.02 (br d, 1H), 2.73 (t, 2H), 1.99-2.05 (m, 1H),1.72-1.76 (m, 1H), 1.62- 1.71 (m, 3H), 1.13-1.60 (m, 6H). 407.3(C₁₃H₂₄N₆O₇S•CF₃COOH) 27.

9.97 (s, 1H), 9.71 (s, 1H), 7.74 (br s, 3H), 4.04 (s, 2H), 4.01 (br s,1H), 3.83 (d, 1H), 3.64 (t, 2H), 3.20 (d, 1H), 3.00- 3.05 (m, 3H),1.98-2.05 (m, 1H), 1.82-1.86 (m, 1H), 1.68-1.73 (m, 1H), 1.58-1.63 (m,1H). 380.2 (C₁₁H₁₉N₅O₈S) 28.

10.03 (br s, 1H), 8.66 (br s, 1H), 4.05-4.12 (m, 1H), 3.96- 4.01 (m,4H), 3.84 (d, 1H), 3.53-3.58 (m, 1H), 3.21 (d, 1H), 3.01 (br d, 1H),1.98- 2.03 (m, 1H), 1.72-1.85 (m, 1H), 1.68-1.71 (m, 1H), 1.57-1.62 (m,1H). 362.2 (C₁₁H₁₇N₅O₇S) 29.

9.49 (s, 1H), 8.08 (s, 1H), 3.98 (br s, 1H), 3.76 (d, 1H), 3.35 (d, 2H),3.20-3.25 (m, 4H), 2.96 (br d, 1H), 1.86-2.06 (m, 1H), 1.57- 1.80 (m,7H). 376.1 (C₁₂H₁₉N₅O₇S) 30.

10.35 (br s, 1H), 10.18 (s, 1H), 8.96 (br s, 2H), 4.18 (t, 1H), 4.01 (brs, 1H), 3.86 (d, 1H), 3.17-3.25 (m, 3H), 3.01 (br d, 1H), 2.31-2.35 (m,1H), 1.98- 2.03 (m, 1H), 1.76-1.91 (m, 4H), 1.66-1.74 (m, 1H), 1.57-1.62(m, 1H). 376.2 (C₁₂H₁₉N₅O₇S) 31.

9.88 (s, 1H), 9.81 (s, 1H), 8.77 (br s, 1H), 8.29 (br s 1H), 4.00 (br s,1H), 3.81 (d, 1H), 3.37- 3.43 (m, 1H), 3.12-3.19 (m, 4H), 2.63 (br d,1H), 2.08- 2.24 (m, 2H), 1.69-2.06 (m, 6H), 1.47-1.61 (m, 3H). 404.2(C₁₄H₂₃N₅O₇S) 32.

10.02 (d, 1H), 9.96 (s, 1H), 8.80 (br s, 1H), 8.68 (br s, 1H), 4.00 (brs, 1H), 3.83 (d, 1H), 3.08-3.17 (m, 6H), 3.00 (br d, 1H), 2.06-2.21 (m,1H), 1.98-2.06 (m, 2H), 1.78- 1.82 (m, 1H), 1.67-1.75 (m, 1H), 1.53-1.65(m, 1H). 376.2 (C₁₂H₁₉N₅O₇S) 33.

10.03 (s, 1H), 9.96 (s, 1H), 8.80 (br s, 1H), 8.68 (br s, 1H), 4.00 (brs, 1H), 3.82 (d, 1H), 3.26-3.37 (m, 4H), 3.17- 3.25 (m, 1H), 3.06-3.10(m, 1H), 3.00 (br d, 1H), 2.16- 2.23 (m, 1H), 2.00-2.05 (m, 1H),1.86-1.85 (m, 1H), 1.65- 1.75 (m, 1H), 1.53-1.61 (m, 1H). 376.1(C₁₂H₁₉N₅O₇S) 34.

10.44 (s, 1H), 10.17 (s, 1H), 9.62 (br s, 1H), 8.92 (br s, 1H),5.48-5.52 (m, 1H), 4.44 (br s, 1H), 4.33 (t, 1H), 4.01 (s, 1H), 3.86 (d,1H), 3.19 (d, 1H), 3.00-3.10 (m, 2H), 2.26- 2.31 (m, 1H), 1.87-2.06 (m,4H), 1.66-1.75 (m, 1H), 1.54-1.62 (m, 1H). 392.3 (C₁₂H₁₉N₅O₈S) 35.

10.28 (s, 1H), 9.11 ( br s, 1H), 8.05 (br s, 2H), 4.29 (t, 1H), 4.03 (brs, 1H), 3.87-3.95 (m, 2H), 3.48-3.53 (m, 2H), 3.04- 3.24 (m, 3H), 3.02(br d, 1H), 2.72-2.79 (m, 1H), 1.99- 2.04 (m, 1H), 1.88-1.93 (m, 2 H),1.69-1.78 (m, 1H), 1.54-1.63 (m, 1H). 391.2 (C₁₀H₂₀N₆O₇S) 36.

10.48 (br s, 1H), 10.20 (s, 1H), 7.73 (d, 1H), 7.32 (br s, 4H),4.16-4.26 (m, 2H), 4.03 (br s, 1H), 3.87 (d, 1H), 3.51- 3.56 (m, 1H),3.01-3.17 (m, 3H), 2.74-2.86 (m, 1H), 1.99-2.05 (m, 1H), 1.55- 1.86 (m,5 H). 433.2 (C₁₃H₂₂N₈O₇S) 37.

D₂O exchange: 3.98 (br s, 1H), 3.85 (d, 1H) 3.17 (br d, 1H), 3.02-3.11(m, 2H), 2.92- 2.98 (m, 1H), 2.77 (t, 1H), 2.25-2.28 (m, 2H), 2.00- 2.04(m, 1H), 1.75-1.86 (m, 3H), 1.60-1.71 (m, 4H), 1.23-1.47 (m, 4H). 418.0(C₁₅H₂₅N₅O₇S) 38.

10.54 (br s, 1H), 10.22 (d, 1H), 8.96 (br s, 2H), 4.09 (d, 1H), 4.02 (brs, 1H), 3.87 (d, 1H), 3.62 (t, 2H), 3.38 (t, 3H), 3.01-3.17 (m, 4H),1.98-2.05 (m, 1H), 1.86-1.88 (m, 1H), 1.68-1.75 (m, 1H), 1.55-1.62 (m,1H). 391.3 (C₁₂H₂₀N₆O₇S•CF₃COOH) 39.

10.46 (s, 1H), 10.18 (s, 1H), 9.37 (br d, 2H), 4.13 (br d, 2H), 4.02 (brs, 1H), 3.86 (br d, 2H), 3.57-3.62 (m, 2H), 3.17 (br d, 3H), 3.02 (br d,1H), 1.98-2.04. (m, 1H), 1.85-1.94 (m, 1H), 1.66-1.76 (m, 1H), 1.56-1.61(m, 1H). 392.2 (C₁₂H₁₉N₅O₈S) 40.

D₂O exchange: 3.97 (br s, 1H), 3.83 (d, 1H), 3.59-3.68 (m, 4H), 3.40 (s,2H), 3.03- 3.06 (m, 6H), 1.98-2.04 (m, 1H), 1.75-1.84 (m, 1H), 1.65-1.73 (m, 1H), 1.57-1.61 (m, 1H). 433.3 (C₁₄H₂₂N₆O₈S) 41.

10.62 (s, 1H), 10.23 (d, 1H), 8.72 (br s, 3H), 8.62 (br s, 1H), 7.94 (t,1H), 7.76 (dd, 1H), 7.47 (t, 1H), 5.09-5.10 (m, 1H), 4.00 (br s, 1H),3.84 (br d, 1H), 3.14-3.21 (m, 1H), 2.99 (br d, 1H), 1.94-2.02 (m, 1H),1.82- 1.91 (m, 1H), 1.66-1.76 (m, 1H), 1.57-1.62 (m, 1H). 413.2(C₁₉H₁₈N₆O₇S•CF₃COOH) 42.

D₂O exchange: 7.33 (s, 1H), 4.00 (br s, 1H), 3.83 (d, 1H), 3.28 (d, 1H),3.00 (br d, 1H), 2.00-2.05 (m, 1H), 1.76- 1.86 (m, 1H), 1.67-1.75 (m,1H), 1.59-1.64 (m, 1H). 405.1 (C₁₁H₁₄N₆O₇S₂)

Example-43 Sodium salt of trans-sulfuric acidmono-[2-(N′-(cyano-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester

Tetrabutylammonium salt of trans-sulfuric acidmono-[2-(N′-(cyano-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester(600 mg, obtained using procedure described in Step-1 to Step-3 ofExample 1 (using cyano acetic acid hydrazide in the place of(S)—N-tert-butoxycarbonyl-pyrrolidine-2-carboxylic acid hydrazide) wasloaded in tetrahydrofuran and water 1:9 mixture (10 ml) and passedslowly through freshly activated Amberlite 200C resin in sodium form(100 gm). The column was eluted with 10% tetrahydrofuran in watermixture. The fractions were analyzed on TLC and desired fractions wereevaporated to remove volatile solvent under vacuum below 40° C. Theaqueous layer was then washed with dichloromethane (25 ml×2) and layerswere separated. The aqueous layer was concentrated under vacuum below40° C. to provide residue, which was azeotroped with acetone andtriturated with diethyl ether to provide a suspension. The suspensionwas filtered to provide title compound (Sodium salt of trans-sulfuricacidmono-[2-(N′-(2-cyano-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester)in 300 mg quantity and in 81% yield.

Analysis: MS (ES−) C₁₀H₁₂N₅O₇SNa, 346.2 (M−1) as a free sulfonic acid;

H¹NMR (DMSO-d₆)=10.2 (s, 1H), 10.05 (s, 1H), 3.99 (s, 1H), 3.82 (d, 1H),3.72 (s, 1H), 3.36 (s, 1H), 3.14 (br d, 1H), 2.99 (d, 1H), 1.98-2.03 (m,1H), 1.75-1.84 (m, 1H), 1.56-1.72 (m, 2H).

Compounds 44 to 52 (Table 2) were using a procedure described inExample-16 and using corresponding R₁CONHNH₂, in the place of cyanoacetic acid hydrazide.

TABLE 2 Example Acid hydrazide Mass (ES-1) as No. (R₁CONHNH₂) R₁ H¹ NMR(DMSO-d₆) free acid (MF) 44. t-Boc—NHNH₂ t-C₄H₉—O—CO— 9.70 (s, 1H), 8.71(s, 1H), 3.98 379.3 (s, 1H), 3.73, (d, 1H), 3.13 (d, (C₁₂H₁₉N₄O₈SNa)1H), 2.97 (br d, 1H), 1.97- 2.01 (m, 1H), 1.73-1.83 (m, 1H), 155-2.72(m, 2H), 1.38 (s, 9H). 45.

10.02 (br s, 2H), 3.98 (br s, 1H), 3.85 (d, 1H), 3.66-2.70 (m, 4H), 3.37(br s, 2H), 3.05 (s, 2H), 2.76 (br s, 4H), 2.00- 2.04 (m, 1H), 1.73-1.82(m, 1H), 1.58-1.70 (m, 2H). 406.3 (C₁₃H₂₀N₅O₈SNa) 46.

11.00 (s, 1H), 10.17 (s, 1H), 8.91 (s, 1H), 8.17-8.20 (m, 3H), 7.74 (s,1H), 4.04 (br s, 1H), 3.91 (d, 1H), 3.06 (br d, 1H), 1.90-2.06 (m, 2H),1.77-1.87 (m, 1H), 1.61-1.77 (m, 2H). 426.9 (C₁₄H₁₅N₆O₈SNa) 47.

10.45 (br s, 1H), 10.08 (br s, 1H), 3.99 (br s, 1H), 3.81 (br d, 1H),3.56-3.58 (m, 4H), 3.41- 3.51 (m, 2H), 2.99-3.10 (m, 2H), 2.06 (br s,2H) 2.01-2.03 (m, 1H), 2.82-1.83 (m, 1H), 1.59-1.72 (m, 2H). 419.9(C₁₃H₁₈N₅O₉SNa) 48.

9.81 (br s, 1H), 9.69 (br s, 1H), 5.77 (s, 2H), 4.21 (t, 1H), 3.98 (brs, 1H), 3.77 (d, 1H), 3.34-3.38 (m, 1H), 3.16-3.29 (m, 2H), 2.96 (br d,1H), 1.73- 1.98 ( m, 6H), 1.58-1.72 (m, 2H). 419.2 (C₁₃H₁₉N₆O₈S•Na) 49.

9.77 (br s, 2H), 5.95 (s, 2H), 5.32 (s, 0.5H), 5.18 (br s 0.5H), 4.38(dd, 1H), 3.98 (br s, 1H), 3.81 (d, 1H), 3.35- 3.59 (m, 2H), 2.97-3.25(m, 1H), 2.96 (br d, 1H), 1.99- 2.39 (m, 2H), 1.82-1.95 (m, 1H),1.75-1.82 (m, 1H), 1.59-1.69 (m, 2H). 437.2 (C₁₃H₁₈N₆O₈FS•Na) 50.

9.83 (br s, 2H), 7.32 (s, 1H), 4.21 (dd, 1H), 3.98 (br s, 1H), 3.77 (d,1H), 3.38-3.44 (m, 1H), 3.21-3.25 (m, 1H), 2.90- 2.98 (m, 4H), 1.56-2.12(m, 8H). 454.2 (C₁₃H₂₀N₅O₉S₂•Na) 51.

D₂O exchange: 3.95-4.05 (m, 2H), 3.10-3.19 (m, 1H), 2.95-3.05 (m, 1H),1.68-1.98 (m, 4H), 1.29 (s, 3H), 1.21 (s, 3H). 374.2 (C₁₂H₁₆N₅O₇S•Na)52.

9.95 (s, 2H), 7.93 (s, 1H), 4.03- 4.05 (m, 1H), 3.99 (br s, 1H), 3.81(d, 1H), 3.19 (d, 1H), 2.98 (br d, 1H), 2.28-2.48 (m, 1H), 1.84-2.25 (m,5H), 1.56-1.75 (m, 2H).

Compounds of the invention from Example 1 to 52 were prepared using(S)-pyrroglutamic acid as a starting compound. The absolutestereochemistry is therefore (2S,5R)7-oxo-1,6-diaza-bicyclo[3.2.1]octane ring. Thus, the compound ofExample-2, trans-sulfuric acidmono-[2-(N′-[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]esterhas the absolute stereochemistry as (2S,5R)-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester.Alternatively, if the starting compound used is (R)-pyrroglutamic acidthe resulting compounds will have (2R,5S) stereochemistry in7-oxo-1,6-diaza-bicyclo[3.2.1]octane ring. A reference to a compoundaccording to the invention also includes corresponding compounds having(2S,5R) and (2R,5S) stereochemistry.

Biological Activity

The biological activity of representative compounds according to theinvention against various bacterial strains was investigated. In atypical study, overnight grown bacterial cultures were dilutedappropriately and inoculated on the agar media containing doublingdilutions of the test compounds. Observation for growth or no growth wasperformed after 16-20 hours of incubation at 35±2° C. in ambient air.The overall procedure was performed as per Clinical and LaboratoryStandards Institute (CLSI) recommendations (Clinical and LaboratoryStandards Institute (CLSI), Performance Standards for AntimicrobialSusceptibility Testing, 20th Informational Supplement, M 100-S20, Volume30, No. 1, 2010). The results of these studies are summarized in Tables3 to 8.

Table 3 details antibacterial activity of representative compoundsaccording to the invention against various E. coli strains (NCTC 13351,M 50 and 7 MP) expressing ESBL (Extended Spectrum Beta Lactamases).

TABLE 3 Antibacterial activity of representative compounds according tothe invention (MIC expressed in mcg/ml) Bacterial Strain Compound of E.coli E. coli E. coli Sr. Example No. NCTC 13351 M 50 7 MP 1. 1 0.0250.25 0.25 2. 2 0.25 0.25 1 3. 3 0.25 0.25 1 4. 4 8 8 16 5. 5 0.25 0.250.5 6. 6 32 64 128 7. 7 2 2 4 8. 8 1 1 2 9. 9 1 2 4 10. 10 1 8 32 11. 112 1 4 12. 12 1 8 32 13. 13 1 1 2 14. 14 0.5 0.25 2 15. 15 8 4 16 16. 161 1 2 17. 17 0.5 0.5 2 18. 18 8 4 32 19. 19 1 1 2 20. 20 2 2 8 21. 21 11 4 22. 22 4 4 8 23. 23 4 4 8 24. 24 1 1 4 25. 25 1 1 4 26. 26 1 1 2 27.27 4 2 8 28. 28 1 1 4 29. 29 32 16 128 30. 30 16 8 32 31. 31 1 1 4 32.32 0.5 0.5 1 33. 33 1 0.5 2 34. 34 2 2 8 35. 35 1 1 4 36. 36 1 1 2 37.37 2 2 4 38. 38 4 2 8 39. 39 4 2 8 40. 40 1 1 4 41. 41 4 4 16 42. 42 3232 64 43. 43 1 2 8 44. 44 32 32 64 45. 45 4 8 8 46. 46 32 64 128 47. 4732 64 128 48. 48 16 8 32 49. 49 32 16 16 50. 50 16 16 32 51. 51 16 16 3252. 52 0.5 0.5 2

Tables 4 and 5 provide antibacterial activity of representativecompounds according to the invention against various Multi DrugResistant (MDR) Gram-negative bacterial strains expressing variousESBLs. The activities are expressed as MICs (mcg/ml). For comparison,the activity of several known antibacterial agents (for example,Ceftazidime, Aztreonam, Imipenem, Ciprofloxacin and Tigecycline) arealso included. As can be seen, the representative compounds according tothe invention exhibit antibacterial activity against various MDRstrains. The data in Table 4 and 5 also indicates that the compoundsaccording to the invention exhibit potent activity against a widevariety of bacteria, even against those producing different types ofbeta-lactamase enzymes. In general, the activity of the compoundsaccording to the invention against various beta-lactamase producingbacterial strains is even better than the other antibacterial agentscurrently employed in the clinical practice to treat such infections.

The antibacterial activity of representative compounds according to theinvention was also investigated in combination with at least oneantibacterial agent using the above study protocol and the results aregiven Table 6. As can be seen, the use of compounds according to theinvention significantly lowered MIC values of the antibacterial agent(e.g. in this case Ceftazidime). The results also suggest the compoundsaccording the invention increase antibacterial effectiveness of theantibacterial agent when said antibacterial agent is co-administeredwith a pharmaceutically effective amount of a compound of Formula (I) ora stereoisomer or a pharmaceutically acceptable salt thereof.

The antibacterial activity of representative compounds according to theinvention was also investigated in combination with a beta-lactamaseinhibitor using the above study protocol and the results are given inTable 7. As can be seen, the compounds according to the invention incombination with a beta lactam inhibitor exhibited excellentantibacterial activity against various bacterial strains. For example, acombination comprising compound of Example 2 (and also Example 3)according to the invention in combination with sulbactam exhibited muchsuperior MIC values compared with when these were used alone. Theresults also suggest that compounds according to the invention incombination with a beta-lactam inhibitor can be effectively used inpreventing or treating a bacterial infection in a subject, includingthose infections caused by bacteria producing one or more beta-lactamaseenzymes.

The antibacterial activity of representative compounds according to theinvention was also investigated in combination with a beta-lactamaseinhibitor and a antibacterial agent using the above study protocol andthe results are given in Table 8. As can be seen, the compoundsaccording to the invention in combination with at least one beta lactaminhibitor and at least one antibacterial agent exhibited excellentantibacterial activity against various bacterial strains. For example, acombination comprising compound of Example 2 (and also Example 3)according to the invention in combination with sulbactam and Cefepimeexhibited better MIC values compared with when these were used alone.The results also suggest that compounds according to the invention incombination with at least one beta-lactam inhibitor and at least oneantibacterial agent can be effectively used in preventing or treating abacterial infection in a subject, including those infections caused bybacteria producing one or more beta-lactamase enzymes.

TABLE 4 Comparative antibacterial activity of representative compoundsaccording to the invention against various Multi Drug Resistant (MDR)Gram negative strains (expressed as MICs (mcg/ml). Class A ESBL Class CESBL KPC ESBL E. Coli E. Coli E. Coli E. Coli E. Coli E. Coli Kpenumoniae K penumoniae K penumoniae Sr. Compound W 13353 W 13351 W13352 M 50 H 484 B 89 H 521 H 523 H 525 1. Ceftazidime 3232 >32 >32 >32 >32 >32 >32 >32 2.Aztreonam >32 >32 >32 >32 >32 >32 >32 >32 >32 3. Imipenem 0.25 0.25 0.250.5 4 0.5 16 16 16 4. Ciprofloxacin >32 0.5 0.12 >32 >32 >32 32 8 32 5.Tigecyclin 1 1 0.25 0.5 0.25 0.5 2 8 2 6. Example 1 0.25 0.5 0.5 0.5 20.5 0.5 0.5 0.5 7. Example 2 0.12 0.25 0.25 0.25 0.12 0.25 0.5 1 0.5 8.Example 3 0.25 0.5 0.5 0.5 0.5 0.25 0.5 0.5 0.5 9. Example 5 0.5 0.250.5 1 1 0.5 1 1 2 10. Example 7 0.5 2 1 2 4 4 2 1 2 11. Example 8 1 1 11 2 1 1 0.5 1 12. Example 9 1 1 1 1 2 1 1 0.5 0.5 13. Example 11 2 2 2 216 2 4 2 2 14. Example 13 1 1 2 1 4 1 1 0.5 1 15. Example 14 0.5 0.5 0.50.5 2 0.5 0.5 0.25 0.25 16. Example 17 0.25 0.5 0.5 0.5 4 0.5 0.5 0.50.5 17. Example 19 2 2 2 2 4 1 1 1 1 18. Example 30 8 16 16 8 8 8 88 >32 19. Example 35 1 1 1 1 1 1 2 1 1 20. Example 38 2 4 4 2 8 2 2 2 221. Example 43 1 1 1 1 8 1 2 1 1

TABLE 5 Comparative antibacterial activity of representative compoundsaccording to the invention against various Multi Drug Resistant (MDR)Gram negative strains (expressed as MICs (mcg/ml). Class B ESBL K.penumoniae E. Coli E. Coli P. aeruginosa Sr. Compound S 48 M 3 M 44 ATCC27853 Ps 21 Ps 32 1. Ceftazidime >32 >32 >32 1 >32 >32 2.Aztreonam >32 >32 >32 2 8 8 3. Imipenem 16 8 32 4 >32 >32 4.Ciprofloxacin >32 >32 >32 0.5 32 0.12 5. Tigecyclin 1 4 0.25 16 16 16 6.Example 1 2 1 0.25 16 16 32 7. Example 2 0.5 2 0.5 8 8 8 8. Example 30.5 0.5 0.12 2 4 4 9. Example 5 2 1 0.5 >32 >32 >32 10. Example 7 4 42 >32 >32 >32 11. Example 8 1 4 0.5 8 16 8 12. Example 9 1 2 0.5 8 8 1613. Example 11 2 8 1 >32 >32 >32 14. Example 13 1 1 1 32 32 16 15.Example 14 4 0.5 0.25 8 16 8 16. Example 17 0.5 0.5 0.5 >32 >32 >32 17.Example 19 4 1 1 32 >32 >32 18. Example 30 >32 8 16 >32 >32 >32 19.Example 35 2 1 2 >32 >32 32 20. Example 38 4 1 4 >32 >32 >32 21. Example43 1 4 0.5 >32 >32 >32

TABLE 6 Antibacterial activity of Ceftazidime in presence ofrepresentative compounds of the invention against various Multi DrugResistant (MDR) Gram negative strains. Ceftazidime MIC (expressed inmcg/ml) K. pneumoniae P. vulgaris ATCC 700603 S-137B (ESBL type: (ESBLtype: Sr. Composition Class A) Class C) 1. Ceftazidime alone >32 >32 2.Ceftazidime + Compound 0.06 1 of Example 1 (4 mcg/ml) 3. Ceftazidime +Compound 0.06 1 of Example 2 (4 mcg/ml) 4. Ceftazidime + Compound 0.06 1of Example 3 (4 mcg/ml) 5. Ceftazidime + Compound 0.25 4 of Example 5 (4mcg/ml) 6. Ceftazidime + Compound 0.06 0.5 of Example 8 (4 mcg/ml) 7.Ceftazidime + Compound 0.12 1 of Example 9 (4 mcg/ml) 8. Ceftazidime +Compound 0.03 0.5 of Example 14 (4 mcg/ml) Note: The MICs of each ofcompounds of Example 1, 2, 3, 5, 8, 9 and 14 when used alone (in theabsence of Ceftazidime) is >32 mcg/ml.

TABLE 7 Antibacterial activity of sulbactam in combination with acompound according to the invention. MIC of sulbactam (expressed inmcg/ml) A. baumannii A. baumannii A. baumannii A. baumannii Sr.Composition J-143 1460648 S-334 G-165 1. Sulbactam alone 32 32 32 32 2.Sulbactam + compound of Example 2 (4 mcg/ml) 4 4 4 2 3. Sulbactam +compound of Example 2 (8 mcg/ml) 4 4 2 2 4. Sulbactam + compound ofExample 3 (4 mcg/ml) 8 4 8 2 5. Sulbactam + compound of Example 3 (8mcg/ml) 1 2 4 2 Standalone MIC of compound of Example 2 and Example 3for each of the strains was >32 mcg/ml.

TABLE 8 Antibacterial activity of an antibacterial agent in combinationwith sulbactam and a compound according to the invention. MIC ofCefepime (expressed in mcg/ml) A. baumannii A. baumannii A. baumannii A.baumannii Sr. Composition J-143 1460648 S-334 G-165 1. Cefepimealone >32 >32 32 >32 2. Cefepime + compound of Example 2 (4 mcg/ml) >3232 32 >32 3. Cefepime + compound of Example 2 (8 mcg/ml) 32 32 32 32 4.Cefepime + Sulbactam (4 mcg/ml) 16 32 16 16 5. Cefepime + Sulbactam (8mcg/ml) 16 16 8 8 6. Cefepime + Sulbactam (8 mcg/ml) + compound ofExample 2 (4 mcg/ml) 0.25 0.25 0.25 0.25 7. Cefepime + Sulbactam (8mcg/ml) + compound of Example 2 (8 mcg/ml) 0.25 0.25 0.25 0.25 8.Cefepime + compound of Example 3 (4 mcg/ml) >32 32 32 >32 9. Cefepime +compound of Example 3 (8 mcg/ml) 32 32 32 32 10. Cefepime + Sulbactam (8mcg/ml) + compound of Example 3 (4 mcg/ml) 0.12 0.12 0.12 0.12 11.Cefepime + Sulbactam (8 mcg/ml) + compound of Example 3 (8 mcg/ml) 0.060.06 0.06 0.06 Standalone MIC of sulbactam for each of the strains was32 mcg/ml. Standalone MIC of compound of Example 2 and Example 3 foreach of the strains was >32 mcg/ml.

The invention claimed is:
 1. A compound of Formula (I)

or a stereoisomer or a pharmaceutically acceptable salt thereof;wherein: R₁ is: (a) hydrogen, (b) (CO)_(n)—R₃, or (c) COOR₄. n is 0, 1or 2; R₂ is: (a) SO₃M, (b) SO₂NH₂, (c) PO₃M, (d) CH₂COOM, (e) CF₂COOM,(f) CHFCOOM, or (g) CF₃; M is hydrogen or a cation; R₃ is: (a) hydrogen,(b) C₁-C₆ alkyl optionally substituted with one or more substituentsindependently selected from halogen, OR₅, CN, COOR₅, CONR₆R₇, NR₆R₇,NR₅COR₈, NR₅CONR₆R₇, heterocyclyl, heteroaryl, cycloalkyl or aryl, (c)CN, (d) NR₆R₇, (e) CONR₆R₇, (f) NHCONR₆R₇, (g) aryl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇, (h) heterocyclyl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇, (i) heteroaryl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇, (j) cycloalkyl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₆R₇, (k) cycloalkyl substituted withC₁-C₆ alkyl wherein C₁-C₆ alkyl is further substituted with one or moresubstituents independently selected from OR₅, NR₆R₇, halogen, CN, orCONR₆R₇, or (i) OR₈; R₄ is: (a) hydrogen, (b) C₁-C₆ alkyl optionallysubstituted with one or more substituents independently selected fromhalogen, OR₅, CN, COOR₅, CONR₆R₇, NR₆R₇, NR₅COR₈, heterocyclyl,heteroaryl, cycloalkyl or aryl, (c) aryl optionally substituted with oneor more substituents independently selected from C₁-C₆ alkyl, OR₅,NR₆R₇, halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl,or NHCONR₆R₇, (d) heterocyclyl optionally substituted with one or moresubstituents independently selected from C₁-C₆ alkyl, OR₅, NR₆R₇,halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, orNHCONR₆R₇, (e) heteroaryl optionally substituted with one or moresubstituents independently selected from C₁-C₆ alkyl, OR₅, NR₆R₇,halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, orNHCONR₆R₇, or (f) cycloalkyl optionally substituted with one or moresubstituents independently selected from C₁-C₆ alkyl, OR₅, NR₆R₇,halogen, CN, CONR₆R₇, SO₂-alkyl, SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, orNHCONR₆R₇; R₅ and R₈ are each independently: (a) hydrogen, or (b) C₁-C₆alkyl optionally substituted with one or more substituents independentlyselected from halogen, CN, CONR₆R₇, NR₆R₇, heterocyclyl, heteroaryl,cycloalkyl or aryl; R₆ and R₇ are each independently: (a) hydrogen, (b)C₁-C₆ alkyl optionally substituted with one or more substituentsindependently selected from halogen, OR₅, CN, COOR₅, CONR₅R₈, NR₅R₈,NR₅COR₈, heterocyclyl, heteroaryl, cycloalkyl or aryl, (c) aryloptionally substituted with one or more substituents independentlyselected from C₁-C₆ alkyl, OR₅, NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl,SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈, (d) heterocyclyloptionally substituted with one or more substituents independentlyselected from C₁-C₆ alkyl, OR₅, NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl,SO₂-aryl, OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈, (e) heteroaryl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈, (f) cycloalkyl optionallysubstituted with one or more substituents independently selected fromC₁-C₆ alkyl, OR₅, NR₅R₈, halogen, CN, CONR₅R₈, SO₂-alkyl, SO₂-aryl,OSO₂-alkyl, OSO₂-aryl, or NHCONR₅R₈, or (g) R₆ and R₇ are joinedtogether to form a four to seven member ring.
 2. A compound accordingclaim 1, selected from: trans-sulfuric acidmono-[2-(N′—[(S)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((R)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-hydrazinocarbonyl-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(amino-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(3-amino-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(4-amino-butanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-((2S)-2-amino-3-hydroxy-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-[(2S,4S)-4-fluoro-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-[(2S,4R)-4-methoxy-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(piperidin-4-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((RS)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((S)-piperidin-3-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((RS)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((S)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((R)-piperidin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(piperazin-4-yl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—((RS)-1-amino-1-phenyl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(3-amino-2,2-dimethyl-propioyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(1-aminomethyl-cyclopropan-1-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(5-amino-pentanoyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;trans-sulfuric acidmono-[2-(N′-(2-amino-thiazol-4-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;or a stereoisomer or a pharmaceutically acceptable salt thereof.
 3. Acompound according claim 1, selected from: Sodium salt of trans-sulfuricacidmono-[2-(N′-(cyano-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt oftrans-N′-(7-oxo-6-sulfooxy-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylicacid)-hydrazinecarboxylic acid tert-butyl ester; Sodium salt oftrans-sulfuric acidmono-[2-(N′-(morpholin-4-yl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′-(6-carboxamido-pyridin-2-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′-(morpholin-4-oxo-carbonyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-1-carbamoyl-pyrrolidin-2-carbony]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′-[(2S,4S)-1-carbamoyl-4-fluoro-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-1-methanesulfonyl-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;Sodium salt of trans-sulfuric acidmono-[2-(N′-(cyano-dimethyl-acetyl)-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester; Sodium salt of trans-sulfuric acidmono-[2-(N′—[(S)-5-oxo-pyrrolidin-2-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester;or a stereoisomer thereof.
 4. A pharmaceutical composition comprising acompound according to any of the claims 1 to
 3. 5. A pharmaceuticalcomposition according to claim 4, further comprising at least onebeta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanicacid, or a pharmaceutically acceptable derivative thereof.
 6. Apharmaceutical composition according to claim 4 or 5, further comprisingat least one antibacterial agent or a pharmaceutically acceptablederivative thereof.
 7. A pharmaceutical composition according to claim6, wherein the antibacterial agent is selected from a group consistingof aminoglycosides, ansamycins, carbacephems, cephalosporins,cephamycins, lincosamides, lipopeptides, macrolides, monobactams,nitrofurans, penicillins, polypeptides, quinolones, sulfonamides,tetracyclines, or oxazolidinone antibacterial agents.
 8. Apharmaceutical composition according to claim 6, wherein theantibacterial agent is a beta-lactam antibacterial agent.
 9. Apharmaceutical composition according to claim 6, wherein saidantibacterial agent is selected from a group consisting of penicillins,penems, carbapenems, cephalosporins, and monobactams.
 10. Apharmaceutical composition according to claim 6, wherein theantibacterial agent is a cephalosporin antibiotic selected from a groupconsisting of cephalothin, cephaloridine, cefaclor, cefadroxil,cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin,cephacetrile, cefotiam, cefotaxime, cefsulodin, cefoperazone,ceftizoxime, cefmenoxime, cefmetazole, cephaloglycin, cefonicid,cefodizime, cefpirome, ceftazidime, ceifriaxone, cefpiramide,cefbuperazone, cefozopran, cefepime, cefoselis, cefluprenam, cefuzonam,cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoximeaxetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil,cefcapene pivoxil or cefditoren pivoxil, cefuroxime, cefuroxime axetil,loracarbacef, ceftaroline and latamoxef.
 11. A pharmaceuticalcomposition according to claim 6, wherein the antibacterial agent isselected from a group consisting of ceftazidime, cefepime, cefpirome,piperacillin doripenem, meropenem, imipenem, ceftaroline andceftolozane.
 12. A pharmaceutical composition according to claim 6,wherein the antibacterial agent is selected from a group consisting ofaminoglycosides, ansamycins, carbacephems, cephalosporins, cephamycins,lincosamides, lipopeptides, macrolides, monobactams, nitrofurans,penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, oroxazolidinone antibacterial agents.
 13. A pharmaceutical compositionaccording to claim 5, comprising (a) trans-sulfuric acidmono-[2-(N′—[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester or a stereoisomer or a pharmaceutically acceptable salt thereof,and (b) sulbactam or a pharmaceutically acceptable derivative thereof.14. A pharmaceutical composition according to claim 5, comprising (a)trans-sulfuric acidmono-[2-(N′—[(R)-pyrrolidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester or a stereoisomer or a pharmaceutically acceptable salt thereof,and (b) sulbactam or a pharmaceutically acceptable derivative thereof.